<SEC-DOCUMENT>0001104659-26-004532.txt : 20260116
<SEC-HEADER>0001104659-26-004532.hdr.sgml : 20260116
<ACCEPTANCE-DATETIME>20260116160521
ACCESSION NUMBER:		0001104659-26-004532
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20260115
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260116
DATE AS OF CHANGE:		20260116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MetaVia Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		26539462

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeuroBo Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20191231

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm263364d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:MTVA="http://metaviatx.com/20260115">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_MTVA_metaviatx.com_20260115 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20260115_20260115 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001638287 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000004" name="dei:EntityCentralIndexKey">0001638287</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mtva-20260115.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-01-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-15</xbrli:startDate>
        <xbrli:endDate>2026-01-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90B_edei--DocumentType_c20260115__20260115_z5mBRe373eke"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b><span>&#160;</span></b></p>

<p style="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported): <span id="xdx_907_edei--DocumentPeriodEndDate_c20260115__20260115_zZMpvelexVpd"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">January 15, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="tm263364d1_8kimg001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b><span id="xdx_907_edei--EntityRegistrantName_c20260115__20260115_zTC0z4etI263" style="text-transform: uppercase"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000011" name="dei:EntityRegistrantName">METAVIA INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in Its Charter)</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20260115__20260115_zSM1ZKa3H2Q3"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityFileNumber_c20260115__20260115_zDtx4kHDXfff"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000013" name="dei:EntityFileNumber">001-37809</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20260115__20260115_zarUKD2Kebf1"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-2389984</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span><span style="font-family: Times New Roman, Times, Serif"><br/>
<span style="font-size: 10pt">File Number)</span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span><span style="font-family: Times New Roman, Times, Serif"><br/>
<span style="font-size: 10pt">Identification No.)</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20260115__20260115_zSYnG21Npefe"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000015" name="dei:EntityAddressAddressLine1">545 Concord Avenue</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20260115__20260115_zDWzeOkf7dw1"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 210</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20260115__20260115_ztmq3TNUJ2M3"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000017" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20260115__20260115_zwkov5XdWucg"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p></td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20260115__20260115_zbm8N2umETne"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000019" name="dei:EntityAddressPostalZipCode">02138</ix:nonNumeric></span></b><br/>
(Zip Code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(<span id="xdx_908_edei--CityAreaCode_c20260115__20260115_zKfoErIFQzRa"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000020" name="dei:CityAreaCode">857</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20260115__20260115_zMhydRLnotFb"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000021" name="dei:LocalPhoneNumber">702-9600</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Not applicable</b></p>

<p style="font: 10pt Times New Roman; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 0.25in; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_900_edei--WrittenCommunications_c20260115__20260115_zvujySzA4XLf"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 0.25in; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20260115__20260115_zgXvJid59W7b"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 0.25in; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20260115__20260115_z8dBWY2j4P43"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 0.25in; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20260115__20260115_zwd67w2MO5mh"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; border-left-width: 0in; border-left-color: Black">Securities
registered pursuant to Section&#160;12(b)&#160;of the Act:</p>




<p style="font: 10pt Times New Roman,serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; font-family: Times New Roman,serif; text-align: center; width: 40%"><span style="font-family: Times New Roman; font-size: 10pt">Title&#160;of&#160;each&#160;class</span></td>
    <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 16%"><p style="font: normal 10pt Times New Roman; margin: 0pt 0; text-align: center">Trading<br/>
                                            Symbol(s)</p></td>
    <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 40%"><p style="font: normal 10pt Times New Roman; margin: 0pt 0; text-align: center">Name&#160;of&#160;each&#160;exchange
                                            on&#160;which&#160;registered</p></td></tr>
  <tr>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><span id="xdx_902_edei--Security12bTitle_c20260115__20260115_zMjmNwOtCvac"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><span id="xdx_905_edei--TradingSymbol_c20260115__20260115_z2Y3256mzsic"><ix:nonNumeric contextRef="AsOf2026-01-15" id="Fact000027" name="dei:TradingSymbol">MTVA</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><span id="xdx_90A_edei--SecurityExchangeName_c20260115__20260115_zHNN3D2AS652"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman; font-size: 10pt">Emerging
growth company&#160;&#160;<span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20260115__20260115_zbazfIopHTi"><ix:nonNumeric contextRef="AsOf2026-01-15" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;15, 2026, MetaVia Inc. (the &#8220;<b><i>Company</i></b>&#8221;)
entered into an Underwriting Agreement (the &#8220;<b><i>Underwriting Agreement</i></b>&#8221;) with Ladenburg Thalmann&#160;&amp; Co.
Inc. (the &#8220;<b><i>Underwriter</i></b>&#8221;), pursuant to which the Company issued and sold, in an underwritten public offering
by the Company (the &#8220;<b><i>Public Offering</i></b>&#8221;), (i)&#160;614,840 Class&#160;A Units (the &#8220;<b><i>Class&#160;A Units</i></b>&#8221;),
with each Class&#160;A Unit consisting of (A)&#160;one share of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<b><i>Common
Stock</i></b>&#8221;), (B)&#160;1.5 Series&#160;C Common Warrants to purchase 1.5 shares of Common Stock (the &#8220;<b><i>Series&#160;C
Common Warrants</i></b>&#8221;), and (C)&#160;1.5 Series&#160;D Common Warrants to purchase 1.5 shares of Common Stock, at a price of
$3.10 per Class&#160;A Unit, and (ii)&#160;1,998,704 Class&#160;B Units (the &#8220;<b><i>Class&#160;B Units</i></b>&#8221;), with each
Class&#160;B Unit consisting of (A)&#160;one pre-funded warrant (the &#8220;<b><i>Pre-Funded Warrants</i></b>&#8221; and, together with
the Series&#160;C Common Warrants and the Series&#160;D Common Warrants, the &#8220;<b><i>Warrants</i></b>&#8221;) to purchase one share
of Common Stock, in lieu of shares of Common Stock, (B)&#160;1.5 Series&#160;C Common Warrants, and (C)&#160;1.5 Series&#160;D Common
Warrants, at a purchase price of $3.099 per Class&#160;B Unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Pre-Funded Warrant has an exercise price
of $0.001 per share and is immediately exercisable and will expire when exercised in full. Under the terms of the Pre-Funded Warrants,
the Company may not affect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any
Pre-Funded Warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the
holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or
any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of Common Stock would or could be aggregated with
the holder&#8217;s or any of the holder&#8217;s affiliates for purposes of Section&#160;13(d)&#160;or Section&#160;16 of the Securities
Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;)) would exceed 4.99% (or, upon election by a holder, 9.99%)
of the number of shares of Common Stock outstanding immediately after giving effect to the exercise (the &#8220;<b><i>Beneficial Ownership
Limitation</i></b>&#8221;), as such percentage ownership is calculated in accordance with Section&#160;13(d)&#160;of the Exchange Act
and the applicable regulations of the Securities and Exchange Commission (the &#8220;<b><i>Commission</i></b>&#8221;). A holder may increase
or decrease the Beneficial Ownership Limitation to a higher or lower percentage (not to exceed 9.99%), effective 61 days after written
notice to the Company. Any such increase or decrease will apply only to that holder and not to any other holder of the Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Series&#160;C Common Warrant has an exercise
price of $3.10 per whole share of Common Stock, subject to certain adjustments. The Series&#160;C Common Warrants are immediately exercisable
and will expire on the five-year anniversary of January&#160;16, 2026. However, under the Series&#160;C Common Warrant, the Company <span style="color: #231f20">may
not affect the exercise of any Series&#160;C Common Warrant, and a holder will not be entitled to exercise any portion of any Series&#160;C
Common Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned
by the holder (together with its affiliates) to exceed the Beneficial Ownership Limitation. </span>A holder may increase or decrease <span style="color: #231f20">the
Beneficial Ownership Limitation to a higher or lower percentage (not to exceed 9.99%), upon at least 61 days&#8217; prior notice from
the holder to the Company. </span>Generally, the Series&#160;C Common Warrants may only be exercised through a cash exercise, however,
the holder may elect to exercise the Series&#160;C Common Warrant through a cashless exercise if at the time of exercise thereof there
is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of, the Common
Stock to the holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Series&#160;D Common Warrant has an exercise
price of $3.10 per whole share of Common Stock, subject to certain adjustments. The Series&#160;D Common Warrants are immediately exercisable
and will expire on the two-year anniversary of January&#160;16, 2026. However, under the Series&#160;D Common Warrant, the Company <span style="color: #231f20">may
not affect the exercise of any Series&#160;D Common Warrant, and a holder will not be entitled to exercise any portion of any Series&#160;D
Common Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned
by the holder (together with its affiliates) to exceed the Beneficial Ownership Limitation. </span>A holder may increase or decrease <span style="color: #231f20">the
Beneficial Ownership Limitation to a higher or lower percentage (not to exceed 9.99%), upon at least 61 days&#8217; prior notice from
the holder to the Company. </span>Generally, the Series&#160;D Common Warrants may only be exercised through a cash exercise, however,
the holder may elect to exercise the Series&#160;D Common Warrant through a cashless exercise if at the time of exercise thereof there
is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of, the Common
Stock to the holder. The Series&#160;D Common Warrants are callable at the Company&#8217;s option following the release of a positive
data readout for its Phase 1b Part&#160;III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction
of certain conditions including that the average trading price of the stock exceeds $4.65 per share for 20 consecutive trading days and
a minimum daily trading volume threshold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Underwriting Agreement, the Company
granted the Underwriter a 45-day option (the &#8220;<b><i>Over-Allotment Option</i></b>&#8221;) to purchase up to 392,030 additional shares
of Common Stock and up to 588,045 additional Series&#160;C Common Warrants and 588,045 additional Series&#160;D Common Warrants, solely
to cover over-allotments. The Over-Allotment Option was exercised in full on January&#160;16, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities were offered by the Company pursuant
to the registration statement on Form&#160;S-1 (File No.&#160;333-292581) and the preliminary prospectus contained therein, which was
initially filed with the Commission on January&#160;5, 2026, and declared effective by the Commission on January&#160;15, 2026 including
the registration statement on Form&#160;S-1MEF (File No.&#160;333-292743) filed on January&#160;15, 2026 (collectively, the &#8220;<b><i>Registration
Statement</i></b>&#8221;). A final prospectus relating to the Public Offering was filed with the Commission on January&#160;16, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;16, 2026, the Public Offering
closed, and the Company issued and sold (i)&#160;1,006,870 Class&#160;A Units (which includes 392,030 shares of Common Stock, 588,045
Series&#160;C Common Warrants and 588,045 Series&#160;D Common Warrants sold pursuant to the exercise of the Over-Allotment Option) and
(ii)&#160;1,998,704 Class&#160;B Units, pursuant to the Registration Statement and the Underwriting Agreement. The net proceeds to the
Company, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately
$7.7 million. The Company intends to use the net proceeds from the Public Offering for working capital and general corporate purposes,
including to continue the clinical development of DA-1726 for the treatment of obesity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Underwriting Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company
and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the <b><i>&#8220;Securities Act&#8221;</i></b>),
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, the Company
and its executive officers and directors have entered into agreements providing that the Company and each of these persons may not, without
the prior written approval of the Underwriter, subject to limited exceptions, offer, sell, transfer or otherwise dispose of the Company&#8217;s
securities until <span style="background-color: white">75 days following the closing of the Public Offering</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;16, 2026, the Company entered
into a warrant agency agreement with the Company&#8217;s transfer agent, Equiniti Trust Company, LLC, which will act as warrant agent
for the Company in connection with the Warrants issued and sold in the Public Offering (the &#8220;<b><i>Warrant Agency Agreement</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summaries of the Underwriting Agreement,
Warrants, and Warrant Agency Agreement do not purport to be complete and are subject to, and qualified in their entirety by, such documents
attached as Exhibits 1.1, 4.1, 4.2, 4.3, and 4.4, respectively, to this Current Report on Form&#160;8-K (this &#8220;<b><i>Current Report</i></b>&#8221;),
which are incorporated herein by reference. The Underwriting Agreement is attached hereto as an exhibit to provide interested persons
with information regarding its terms but is not intended to provide any other factual information about the Company. The representations,
warranties and covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement as of specific
dates indicated therein, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed
upon by the parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution
of the Underwriting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01</b></span></td>
    <td style="width: 90%; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&#160;15, 2026, the Company issued a
press release regarding the pricing of the Public Offering, and on January&#160;16, 2026, the Company issued a press release regarding
the closing of the Public Offering. Copies of such press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cautionary Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report contains &#8220;forward-looking&#8221;
statements within the meaning of the Securities Act, the Exchange Act, and of the &#8220;safe harbor&#8221; provisions of the Private
Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected net proceeds of the Public
Offering, the anticipated use of net proceeds of the Public Offering and satisfaction of the closing conditions of the Public Offering.
Statements including words such as &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; &#8220;expect,&#8221; &#8220;will
be,&#8221; &#8220;develop,&#8221; &#8220;signal,&#8221; &#8220;potential,&#8221; &#8220;anticipate&#8221; or &#8220;ongoing&#8221; and
statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well
as assumptions, which, if they do not fully materialize or prove incorrect, could cause the Company&#8217;s results to differ materially
from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties
that may cause the Company&#8217;s actual activities or results to differ significantly from those expressed in any forward-looking statement,
including risks and uncertainties disclosed in its Registration Statement. Forward-looking statements in this Current Report on Form&#160;8-K
speak only as of the date hereof, and the Company specifically disclaims any obligation to update these forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="width: 97%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="width: 2%; padding-bottom: 1.75pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement dated as of January&#160;15, 2026, by and between MetaVia Inc. and Ladenburg Thalmann&#160;&amp; Co. Inc.</span></a></td></tr>
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Pre-Funded Warrant.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Series&#160;C Common Warrant. </span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Series&#160;D Common Warrant.</span></a></td></tr>
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="tm263364d1_ex4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="tm263364d1_ex4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agency Agreement.</span></a></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Press Release dated January&#160;15, 2026.</span></a></td></tr>
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><a href="tm263364d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm263364d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Press Release dated January&#160;16, 2026.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within Inline XBRL document).</span></td></tr>
  </table>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MetaVia Inc.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>
    &#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 48%">
    Date:
    January&#160;16, 2026</td>
    <td style="white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <i>Hyung Heon Kim</i></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Hyung Heon Kim</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8203;</i></span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8203;</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLMbKrg3HSriFBkivlaXSXFrRlqnfpJ/ad0QQyAk955cIQZiRUtdIcNpnmdwwLqplEPIsURGc0HvSNebBPzM8aqtY2Vct/7AlDyDnpmE8uzvnbPVFosE5Hgop8N4DHKURFOYbUXw1VMypS7QOK0qUKaAPVPDGp3iV//hoJ5kqH51SUdkq8kkEIWyl98QyyiGHbXqQXyzkGWpCAZdBWLFdG+8a/F0aL4kLCqsfZzt6X8HH8bkSlQ= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm263364d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>614,840 SHARES <FONT STYLE="text-transform: uppercase">of
Common Stock,</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,998,704 PRE-FUNDED <FONT STYLE="text-transform: uppercase">Warrants
TO PURCHASE UP TO </FONT>1,998,704 <FONT STYLE="text-transform: uppercase">SHARES OF COMMON STOCK,</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,920,316 SERIES C <FONT STYLE="text-transform: uppercase">Warrants
TO PURCHASE UP TO </FONT>3,920,316 <FONT STYLE="text-transform: uppercase">SHARES OF COMMON STOCK AND</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,920,316 SERIES D <FONT STYLE="text-transform: uppercase">Warrants
TO PURCHASE UP TO </FONT>3,920,316 <FONT STYLE="text-transform: uppercase">SHARES OF COMMON STOCK</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>METAVIA INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 458.05pt">January&nbsp;15, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As the Representative of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several underwriters, if any, named in <U>Schedule
I</U> hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">640 Fifth Avenue, 4th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, MetaVia Inc.,
a corporation incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation,
all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of MetaVia Inc., the &ldquo;<U>Company</U>&rdquo;),
hereby confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;) with the several underwriters, if any (such underwriters, including
the Representative (as defined below), the &ldquo;<U>Underwriters</U>&rdquo; and each an &ldquo;<U>Underwriter</U>&rdquo;), named in <U>Schedule
I</U> hereto for which Ladenburg Thalmann&nbsp;&amp; Co. Inc. is acting as representative to the several Underwriters (the &ldquo;<U>Representative</U>&rdquo;
and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term
Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is understood that the
several Underwriters are to make a public offering of the Public Securities as soon as the Representative deems it advisable to do so.
The Public Securities are to be initially offered to the public at the public offering price set forth in the Prospectus. The Representative
may from time to time thereafter change the public offering price and other selling terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is further understood that
you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities and, if any, the Option Securities
in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section&nbsp;1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled
by or is under common control with such Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Closing Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the hour and the date on the Trading Day on which all conditions precedent to (i)&nbsp;the Underwriters&rsquo; obligations
to pay the Closing Purchase Price and (ii)&nbsp;the Company&rsquo;s obligations to deliver the Closing Securities, in each case, have
been satisfied or waived, but in no event later than 10:00 a.m.&nbsp;(New York City time) on the first (1st) Trading Day following the
date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a day that is not a Trading
Day or after 4:00 p.m.&nbsp;(New York City time) and before midnight (New York City time) on a Trading Day) or at such earlier time as
shall be agreed upon by the Representative and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(b), which aggregate purchase price shall be
net of the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Securities</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Series&nbsp;C Warrants</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Series&nbsp;D Warrants</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;2.1(a)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Combined
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Auditor</U>&rdquo; means BDO USA, P.C., with offices located at One International Place, Boston, Massachusetts 02110.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Honigman LLP, with offices located at 650 Trade Centre Way, Suite&nbsp;200, Kalamazoo, Michigan 49002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman&nbsp;&amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Execution
Date</U>&rdquo; shall mean the date on which the parties execute and enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock, options, restricted stock units or other equity-based awards
to employees, officers, directors or consultants of the Company pursuant to any equity compensation plan duly adopted for such purpose
by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, provided that any such securities issued to consultants are issued
as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing
of any registration statement in connection therewith within seventy five (75) days following the Closing Date, (b)&nbsp;securities upon
the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or
convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been
amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or
conversion price of such securities or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to acquisitions
or strategic transactions (including, without limitation, joint venture, co-marketing, co-development or other collaboration agreements)
approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith within seventy five (75) days following the Closing Date, and provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity
whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo; means the Foreign Corrupt
Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FINRA</U>&rdquo;
means the Financial Industry Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means (a)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
the ordinary course of business), (b)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except
guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (c)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with
GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreements</U>&rdquo; means the lock-up agreements that are delivered on the date hereof by each of the Company&rsquo;s officers and directors
and the holders of Common Stock and Common Stock Equivalents identified on <U>Schedule II</U> hereto, in the form of <U>Exhibit&nbsp;A</U>
attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii)&nbsp;a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of
the Company and the Subsidiaries, taken as a whole or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Offering</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;2.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option
Closing Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option Closing Purchase Price</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;2.2(b), which aggregate purchase price shall be net of the underwriting discounts
and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option
Securities</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Option
Warrants</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means the pre-funded Common Stock purchase warrants delivered to the Underwriters in accordance with Section&nbsp;2.1(a)(ii),
which Pre-Funded Warrants shall be immediately exercisable at any time until all the Pre-Funded Warrants are exercised in full, in the
form of <U>Exhibit&nbsp;B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus relating to the Public Securities included in the Registration Statement or filed
with the Commission pursuant to Rule&nbsp;424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or, to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means, if any, any supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that
is filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Public
Securities</U>&rdquo; means, collectively, the Closing Securities and, if any, the Option Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means, collectively, the various parts of the registration statement prepared by the Company on Form&nbsp;S-1 (File
No.&nbsp;333-292581) with respect to the Public Securities, each as amended as of the date hereof, including the Preliminary Prospectus,
the Prospectus and Prospectus Supplement, if any, and all exhibits filed with or incorporated by reference into such registration statement,
and includes any Rule&nbsp;462(b)&nbsp;Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo; means Rule&nbsp;424
promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from time to time, or any
similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Public Securities, which was filed
with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule&nbsp;462(b)&nbsp;promulgated by
the Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Closing Securities, the Option Securities and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;C
Warrants</U>&rdquo; means collectively, the Series&nbsp;C Common Stock purchase warrants delivered to the Underwriters in accordance with
Section&nbsp;2.1(a)(iii)&nbsp;and Section&nbsp;2.2, which Series&nbsp;C Warrants shall be exercisable at any time on or after the issuance
date and have a term of exercise equal to five (5)&nbsp;years from the initial exercise date, in the form of <U>Exhibit&nbsp;C</U> attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;C
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Series&nbsp;C Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;D
Warrants</U>&rdquo; means collectively, the Series&nbsp;D Common Stock purchase warrants delivered to the Underwriters in accordance with
Section&nbsp;2.1(a)(iv)&nbsp;and Section&nbsp;2.2, which Series&nbsp;D Warrants shall be exercisable at any time on or after the issuance
date and have a term of exercise equal to two (2)&nbsp;years from the initial exercise date, in the form of <U>Exhibit&nbsp;D</U> attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Series&nbsp;D
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Series&nbsp;D Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Share
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section&nbsp;2.1(a)(i)&nbsp;and Section&nbsp;2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo; means any of
the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American,
the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors
to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Warrant Agency Agreement, the Lock-Up Agreements, and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with offices located at 6201 15th Avenue,
Brooklyn, New York 11219, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means the warrant agency agreement dated on or about the Closing Date, among the Company and the Transfer
Agent in the form of <U>Exhibit&nbsp;E</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Pre-Funded Warrants, the Series&nbsp;C Warrants and the Series&nbsp;D Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate 614,840 shares of Common Stock,
Pre-Funded Warrants exercisable for an aggregate of 1,998,704 shares of Common Stock, Series&nbsp;C Warrants exercisable for an aggregate
of 3,920,316 shares of Common Stock and Series&nbsp;D Warrants exercisable for an aggregate of 3,920,316 shares of Common Stock and each
Underwriter agrees to purchase, severally and not jointly, at the Closing, the following securities of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
number of shares of Common Stock (the &ldquo;<U>Closing Shares</U>&rdquo;) set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Pre-Funded
Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof,
which Pre-Funded Warrants shall have an exercise price of $0.001, subject to adjustment as provided therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Series&nbsp;C
Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof
(the &ldquo;<U>Closing Series&nbsp;C Warrants</U>&rdquo;), which Series&nbsp;C Warrants shall have an exercise price of $3.10, subject
to adjustment as provided therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Series&nbsp;D
Warrants to purchase up to the number of shares of Common Stock set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof
(the &ldquo;<U>Closing Series&nbsp;D Warrants</U>&rdquo;, and, collectively with the Closing Shares, Pre-Funded Warrants and Closing Series&nbsp;C
Warrants, the &ldquo;<U>Closing Securities</U>&rdquo;), which Series&nbsp;D Warrants shall have an exercise price of $3.10, subject to
adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereto (the &ldquo;<U>Closing Purchase Price</U>&rdquo;). The combined purchase price for one Share, one and a half Series&nbsp;C
Warrants and one and a half Series&nbsp;D Warrants shall be $2.821 (the &ldquo;<U>Combined Purchase Price</U>&rdquo;), which shall be
allocated as $2.8028 per Share (the &ldquo;<U>Share Purchase Price</U>&rdquo;), $0.0091 per one and a half Series&nbsp;C Warrants and
$0.0091 per one and a half Series&nbsp;D Warrants (the &ldquo;<U>Warrant Purchase Price</U>&rdquo;). The combined purchase price for one
Pre-Funded Warrant, one and a half Series&nbsp;C Warrants and one and a half Series&nbsp;D Warrants shall be $2.82009, which shall be
allocated as $2.80189 per Pre-Funded Warrant, $0.0091 per one and a half Series&nbsp;C Warrants and $0.0091 per one and a half Series&nbsp;D
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>On
the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available funds
equal to such Underwriter&rsquo;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its respective
Closing Securities and the Company shall deliver the other items required pursuant to Section&nbsp;2.3 deliverable at the Closing. Upon
satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of EGS or such
other location as the Company and Representative shall mutually agree (including remotely by electronic transmission). The Public Securities
are to be offered initially to the public at the offering price set forth on the cover page&nbsp;of the Prospectus (the &ldquo;<U>Offering</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company acknowledges and agrees that, with respect to any Notice(s)&nbsp;of Exercise (as defined in the Pre-Funded Warrants) delivered
by a Holder (as defined in the Pre-Funded Warrants) on or prior to 12:00 p.m.&nbsp;(New York City time) on the Trading Day immediately
prior to the Closing Date, which Notice(s)&nbsp;of Exercise may be delivered at any time after the time of execution of this Agreement,
the Company shall deliver the Pre-Funded Warrant Shares subject to such notice(s)&nbsp;to the Holder by 4:00 p.m.&nbsp;(New York City
time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants). The Company
acknowledges and agrees that the Holders are third-party beneficiaries of this covenant of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Option
to Purchase Additional Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative
is hereby granted an option (the &ldquo;<U>Option</U>&rdquo;) to purchase, in the aggregate, up to 392,030 shares of Common Stock (the
 &ldquo;<U>Option Shares</U>&rdquo;), Series&nbsp;C Warrants to purchase up to 588,045 shares of Common Stock (the &ldquo;<U>Option Series&nbsp;C
Warrants</U>&rdquo;), and Series&nbsp;D Warrants to purchase up to 588,045 shares of Common Stock (the &ldquo;<U>Option Series&nbsp;D
Warrants</U>&rdquo; and together with the Option Series&nbsp;C Warrants, the &ldquo;Option Warrants&rdquo;, and collectively with the
Option Shares, the &ldquo;<U>Option Securities</U>&rdquo;) which may be purchased in any combination of Option Shares and/or Option Warrants
at the Share Purchase Price and/or Warrant Purchase Price, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
connection with an exercise of the Option, (a)&nbsp;the purchase price to be paid for the Option Shares is equal to the product of the
Share Purchase Price multiplied by the number of Option Shares to be purchased and (b)&nbsp;the purchase price to be paid for the Option
Warrants is equal to the product of the Warrant Purchase Price multiplied by the number of Option Warrants to be purchased (the aggregate
purchase price to be paid on an Option Closing Date, the &ldquo;<U>Option Closing Purchase Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Option granted pursuant to this Section&nbsp;2.2 may be exercised by the Representative as to all (at any time) or any part (from time
to time) of the Option Securities within forty-five (45) days after the Execution Date. An Underwriter will not be under any obligation
to purchase any Option Securities prior to the exercise of the Option by the Representative. The Option granted hereby may be exercised
by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail or electronic
transmission setting forth the number of Option Shares and/or Option Warrants to be purchased and the date and time for delivery of and
payment for the Option Securities (each, an &ldquo;<U>Option Closing Date</U>&rdquo;), which will not be later than one (1)&nbsp;full
Business Day after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices
of EGS or at such other place (including remotely by other electronic transmission) as shall be agreed upon by the Company and the Representative.
If such delivery and payment for the Option Securities does not occur on the Closing Date, each Option Closing Date will be as set forth
in the notice. Upon exercise of the Option, the Company will become obligated to convey to the Underwriters, and, subject to the terms
and conditions set forth herein, the Underwriters will become obligated to purchase, the number of Option Shares and/or Option Warrants
specified in such notice. The Representative may cancel the Option at any time prior to the expiration of the Option by written notice
to the Company. On each Option Closing Date (each, an &ldquo;<U>Option Closing</U>&rdquo;), if any, each Underwriter shall deliver or
cause to be delivered to the Company, via wire transfer, immediately available funds equal to such Underwriter&rsquo;s Option Closing
Purchase Price and the Company shall deliver to, or as directed by, such Underwriter its respective Option Securities and the Company
shall deliver the other items required pursuant to Section&nbsp;2.3 at the Option Closing. Upon satisfaction of the covenants and conditions
set forth in Sections 2.3 and 2.4, the Option Closing shall occur at the offices of the Representative or such other location as the Company
and Representative shall mutually agree (including remotely by electronic transmission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Deliveries</U>.
The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shares shall be
delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing Date, the Pre-Funded Warrants via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts
of the several Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing Date, the Closing Series&nbsp;C Warrants and the Closing Series&nbsp;D Warrants and, as to each Option Closing Date, if any,
the applicable Option Warrants via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several
Underwriters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing Date, the Warrant Agency Agreement duly executed by the parties thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance
letter, substantially in form and substance reasonably satisfactory to the Representative and the favorable opinion of intellectual property
legal counsel to the Company addressed to the Underwriters and in form and substance satisfactory to the Representative, and as to each
Option Closing Date, if any, a bring-down opinion, including, without limitation, a negative assurance letter from Company Counsel in
form and substance reasonably satisfactory to the Representative and the bring-down opinion of intellectual property legal counsel to
the Company addressed to the Underwriters and in form and substance satisfactory to the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Contemporaneously
herewith, a cold comfort letter, addressed to the Underwriters and in form and substance reasonably satisfactory to the Representative
from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down letter dated as of the Closing Date and
each Option Closing Date, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>On
the Closing Date and on each Option Closing Date, if any, the duly executed and delivered Officer&rsquo;s Certificate, substantially in
the form required by <U>Exhibit&nbsp;F</U> attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>On
the Closing Date and on each Option Closing Date, if any, the duly executed and delivered Secretary&rsquo;s Certificate, substantially
in the form required by <U>Exhibit&nbsp;G</U> attached hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Contemporaneously
herewith, the duly executed and delivered Lock-Up Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
Conditions</U>. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option Closing Date,
if any, are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company already
qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the Company contained
herein (unless as of a specific date therein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been performed
in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
delivery by the Company of the items set forth in Section&nbsp;2.3 of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Registration Statement shall be effective on the date of this Agreement and at each of the Closing Date and each Option Closing Date,
if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose
shall have been instituted or, to the Company&rsquo;s knowledge, shall be pending or contemplated by the Commission and any request on
the part of the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation allowable
or payable to the Underwriters as described in the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Closing Shares, the Warrant Shares and the Option Shares have been approved for listing on the Trading Market; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prior
to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have been no material adverse change or
development involving a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise,
of the Company from the latest dates as of which such condition is set forth in the SEC Reports, Registration Statement, Preliminary Prospectus
and Prospectus; (ii)&nbsp;no action suit or proceeding, at law or in equity, shall have been pending or, to the Company&rsquo;s knowledge,
threatened against the Company or any Affiliate of the Company before or by any court or federal or state commission, board or other administrative
agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial
condition or income of the Company, except as set forth in the SEC Reports, Registration Statement, Preliminary Prospectus and Prospectus;
(iii)&nbsp;no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or to the
Company&rsquo;s knowledge threatened by the Commission with respect to the Company; and (iv)&nbsp;the Registration Statement, Preliminary
Prospectus and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be
stated therein in accordance with the Securities Act and the rules&nbsp;and regulations thereunder and shall conform in all material respects
to the requirements of the Securities Act and the rules&nbsp;and regulations thereunder, and none of the Registration Statement, Preliminary
Prospectus or the Prospectus or any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Execution Date, as of the Closing
Date and as of each Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries or any of them in
the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and
the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with
the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and
contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Public Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such
as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;as have been complied with,
waived, obtained or made by the Company, (ii)&nbsp;the filing with the Commission of the Prospectus or Prospectus Supplement, if any,
(iii)&nbsp;as may be required by the Trading Market and (iv)&nbsp;such filings as are required to be made under applicable state securities
laws or blue sky laws or the rules&nbsp;of FINRA (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Statement</U>. The Company has filed with the Commission the Registration Statement, including any related Prospectus or Prospectuses,
for the registration of the Public Securities under the Securities Act, which Registration Statement has been prepared by the Company
in all material respects in conformity with the requirements of the Securities Act and the rules&nbsp;and regulations of the Commission
under the Securities Act. The Registration Statement has been declared effective by the Commission on January&nbsp;15, 2026. The Company
has advised the Representative of all further information (financial and other) with respect to the Company required to be set forth therein
in the Registration Statement, the Preliminary Prospectus and the Prospectus. Any reference in this Agreement to the Registration Statement,
the Preliminary Prospectus, the Prospectus or any Prospectus Supplement shall be deemed to refer to and include the documents incorporated
by reference therein; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
with respect to the Registration Statement, the Preliminary Prospectus, the Prospectus or any Prospectus Supplement shall be deemed to
refer to and include the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Preliminary
Prospectus, the Prospectus or any Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference. All references
in this Agreement to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo;
 &ldquo;described,&rdquo; &ldquo;referenced,&rdquo; &ldquo;set forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the
Preliminary Prospectus, the Prospectus or any Prospectus Supplement (and all other references of like import) shall be deemed to mean
and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in
the Registration Statement, the Preliminary Prospectus, the Prospectus or any Prospectus Supplement, as the case may be. No stop order
suspending the effectiveness of the Registration Statement or the use of the Preliminary Prospectus, the Prospectus or any Prospectus
Supplement has been issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company's knowledge, is
threatened by the Commission. For purposes of this Agreement, &ldquo;<U>free writing prospectus</U>&rdquo; has the meaning set forth in
Rule&nbsp;405 under the Securities Act. The Company will not, without the prior consent of the Representative, prepare, use or refer to,
any free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of Securities</U>. The Public Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant
Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear
of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common
Stock issuable pursuant to this Agreement and the Warrants. The holder of the Public Securities will not be subject to personal liability
by reason of being such holder. The Public Securities are not and will not be subject to the preemptive rights of any holders of any security
of the Company or similar contractual rights granted by the Company. All corporate action required to be taken for the authorization,
issuance and sale of the Public Securities has been duly and validly taken. The Public Securities conform in all material respects to
all statements with respect thereto contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization</U>.
The capitalization of the Company is as set forth in the Registration Statement, the Preliminary Prospectus, the Prospectus or any Prospectus
Supplement as of the dates referred to therein. The Company has not issued any capital stock since the filing of its most recently filed
periodic report under the Exchange Act, other than pursuant to an At the Market Offering Agreement with the Underwriter as sales agent,
the exercise of employee stock options, the issuance of equity-based awards pursuant to the Company&rsquo;s equity compensation plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the filing date of the most recently filed
periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the
Public Securities and as disclosed (or incorporated by reference) in the Registration Statement, the Preliminary Prospectus, the Prospectus
or any Prospectus Supplement, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person
any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock
Equivalents or the capital stock of any Subsidiary. The issuance and sale of the Public Securities will not obligate the Company or any
Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Underwriters). Except as set forth in SEC
Reports, there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise,
conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. Except
as a result of the purchase and sale of the Public Securities, or as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. The authorized shares of the Company conform in all
material respects to all statements relating thereto contained in the Registration Statement and the Prospectus. The offers and sales
of the Company&rsquo;s securities were at all relevant times either registered under the Securities Act and the applicable state securities
or Blue Sky laws or, based in part on the representations and warranties of the purchasers, exempt from such registration requirements.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the
Public Securities. Except as set forth in SEC Reports, there are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary
Prospectus, the Prospectus and any Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in
all material respects with applicable accounting requirements and the rules&nbsp;and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. The agreements and documents described in the Registration Statement, the Preliminary
Prospectus, the Prospectus, any Prospectus Supplement and the SEC Reports conform to the descriptions thereof contained therein and there
are no agreements or other documents required by the Securities Act and the rules&nbsp;and regulations thereunder to be described in the
Registration Statement, the Preliminary Prospectus, the Prospectus, any Prospectus Supplement or the SEC Reports or to be filed with the
Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however
characterized or described) to which the Company is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred
to in the Registration Statement, the Preliminary Prospectus, the Prospectus, any Prospectus Supplement or the SEC Reports, or (ii)&nbsp;is
material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is in full force and effect in
all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance
with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the
federal and state securities laws, and (z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefore may be brought. None
of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the best of the Company&rsquo;s knowledge,
any other party is in default thereunder and, to the best of the Company&rsquo;s knowledge, no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a default thereunder. To the best of the Company&rsquo;s knowledge, performance
by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the
Company or any of its assets or businesses, including, without limitation, those relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i)&nbsp;there has been no
event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the
Company has not incurred any material liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred
in the ordinary course of business consistent with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s
financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method
of accounting, and (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders
or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v)&nbsp;the Company has not issued
any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity compensation plans. The Company
does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Public
Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties,
operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the
time this representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that this
representation is made. Unless otherwise disclosed in an SEC Report filed prior to the date hereof, the Company has not: (i)&nbsp;issued
any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend
or made any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Public
Securities or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.
Neither the Company nor any Subsidiary, nor to the Company&rsquo;s knowledge, any current director or officer thereof, is or has been
the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of
fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the
Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act
or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where
the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other governmental
authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each, a &ldquo;<U>Material
Permit</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit. The disclosures in the Registration Statement concerning the effects of Federal, State, local and all foreign
regulation on the Company&rsquo;s business as currently contemplated are correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights to
lease or otherwise use, all real property and all personal property (excluding Intellectual Property Rights, which are addressed below)
that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i)&nbsp;Liens
as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
property by the Company and the Subsidiaries and (ii)&nbsp;Liens for the payment of federal, state or other taxes, for which appropriate
reserves have been made therefor in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any
real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable
leases with which the Company and the Subsidiaries are in compliance, except where failure to be in compliance could not reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
do so could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the
rights of any Person, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transactions
With Affiliates and Employees</U>. Except as set forth in the Registration Statement, the Preliminary Prospectus, the Prospectus, any
Prospectus Supplement or the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of
the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary
(other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from
or lending of money to or otherwise requiring payments to or from, any officer, director or such employee or, to the knowledge of the
Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee,
stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary, bonus or consulting fees
for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits,
including equity based award agreements under any equity compensation plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Subject to the material
weaknesses identified in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations,
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization,
and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act
is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The
Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Fees</U>. Except as set forth in the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company,
any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. To the Company&rsquo;s knowledge, there
are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its stockholders that
may affect the Underwriters&rsquo; compensation, as determined by FINRA. Except as disclosed in the SEC Reports, the Company has not made
any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&rsquo;s fee, consulting fee or
otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided
capital to the Company; (ii)&nbsp; any FINRA member; or (iii)&nbsp;any person or entity that has any direct or indirect affiliation or
association with any FINRA member, within the twelve months prior to the Execution Date. None of the net proceeds of the Offering will
be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Public Securities will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so as to reasonably assure that it will not become an &ldquo;investment company&rdquo;
subject to registration under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights</U>. Except as disclosed in SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration
under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as disclosed in the SEC Reports, the Registration Statement, the Preliminary Prospectus, the Prospectus or any Prospectus Supplement,
the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is
or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such
Trading Market. The Company is, and, following the Closing hereunder, has no reason to believe that it will not in the foreseeable future
continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic
transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the
fees of the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer, except
where such nonpayment would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disclosure;
10b-5</U>. The Registration Statement (and any further documents to be filed with the Commission in connection with the Offering) contains
all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto,
if any, at the time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable
rules&nbsp;and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The Preliminary Prospectus, Prospectus and any Prospectus Supplement, each as of its respective date, comply in
all material respects with the Securities Act and the Exchange Act and the applicable rules&nbsp;and regulations. Each of the Preliminary
Prospectus, Prospectus and any Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. The SEC Reports, when they were filed with the Commission, conformed in
all material respects to the requirements of the Exchange Act and the applicable rules&nbsp;and regulations, and none of such documents,
when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary
to make the statements therein (with respect to the SEC Reports incorporated by reference in the Preliminary Prospectus, Prospectus or
Prospectus Supplement), in light of the circumstances under which they were made not misleading; and any further documents so filed and
incorporated by reference in the Preliminary Prospectus, Prospectus or Prospectus Supplement, when such documents are filed with the Commission,
will conform in all material respects to the requirements of the Exchange Act and the applicable rules&nbsp;and regulations, as applicable,
and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting
any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information
set forth therein is required to be filed with the Commission as of the date this representation is made, including the Closing Date and
the Option Closing Date, if any. Notwithstanding the foregoing, the Company makes no representation or warranty with respect to any underwriter
information provided for use in the Registration Statement and Prospectus, which shall be limited to the information in the section titled
 &ldquo;Underwriting&rdquo; in the Registration Statement with respect to the selling concessions and the information in the subsection
of the Underwriting section with respect to &ldquo;Stabilization, Short Positions and Penalty Bids.&rdquo; There are no documents required
to be filed with the Commission in connection with the transaction contemplated hereby that (x)&nbsp;have not been filed as required pursuant
to the Securities Act or (y)&nbsp;will not be filed within the requisite time period. There are no contracts or other documents required
to be described in the Preliminary Prospectus, Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration
Statement, which have not been described or filed as required. The press releases disseminated by the Company during the twelve months
preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made and when made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Integrated Offering</U>. Neither the Company, nor to the Company&rsquo;s knowledge, any of its Affiliates, nor any Person acting on its
or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would cause this offering of the Public Securities to be integrated with prior offerings by the Company for purposes
of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Public Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)&nbsp;the
current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured and
unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company
nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed, or secured all extensions for the filing of, all applicable
United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required to be
filed through the date hereof in any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments
and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii)&nbsp;has set
aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. The provisions for taxes
payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all material
accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements.
The term &ldquo;taxes&rdquo; means all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use,
ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp,
occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatsoever,
together with any interest and any penalties, additions to tax, or additional amounts with respect thereto. The term &ldquo;returns&rdquo;
means all returns, declarations, reports, statements, and other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA. The
Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply
in all material respects with the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accountants</U>.
To the knowledge and belief of the Company, the Company Auditor (i)&nbsp;is an independent registered public accounting firm as required
by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2025. The Company Auditor has not, during the periods covered
by the financial statements included in the Prospectus, provided to the Company any non-audit services, as such term is used in Section&nbsp;10A(g)&nbsp;of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules&nbsp;and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would
not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the
FDA or any other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of
advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold on any clinical
investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company or any of its Subsidiaries,
(v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&nbsp;otherwise
alleges any violation of any laws, rules&nbsp;or regulations by the Company or any of its Subsidiaries, and which, either individually
or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws, rules&nbsp;and regulations of the FDA.&nbsp; The Company has
not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock
Incentive Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock incentive plans was granted (i)&nbsp;in
accordance with the terms of one of the Company&rsquo;s stock incentive plans and (ii)&nbsp;with an exercise price at least equal to the
fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company&rsquo;s stock incentive plans has been backdated. The Company has not knowingly granted, and there is
no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant
of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their
financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Representative&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in substantial compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires completed by each of the Company&rsquo;s
directors and officers prior to the Offering and in the Lock-Up Agreement provided to the Underwriters in connection with the Offering
is true and correct in all material respects and the Company has not become aware of any information which would cause the information
disclosed in such questionnaires become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>FINRA
Affiliation</U>. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of 5% or more of the Company&rsquo;s unregistered
securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules&nbsp;and
regulations of FINRA) that is participating in the Offering. The Company will advise the Representative and EGS if it learns that any
officer, director or owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock or Common Stock Equivalents is or becomes
an affiliate or associated person of a FINRA member firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Officers&rsquo;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative or EGS shall
be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Board
of Directors</U>. The Board of Directors is comprised of the persons set forth in the Company&rsquo;s Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2024 filed with the Commission on March&nbsp;20, 2025. The qualifications of the persons serving
as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated
thereunder applicable to the Company and the rules&nbsp;of the Trading Market. At least one member of the Board of Directors qualifies
as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated thereunder
and the rules&nbsp;of the Trading Market. In addition, at least a majority of the persons serving on the Board of Directors qualify as
 &ldquo;independent&rdquo; as defined under the rules&nbsp;of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cybersecurity</U>.&nbsp;
(i)(x)&nbsp;To the Company&rsquo;s knowledge, there has been no security breach or other compromise of or relating to any of the Company&rsquo;s
or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
 &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge
of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii)&nbsp;the Company and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes
and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory authority, internal policies
and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data
from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and
Data; and (iv)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Laws</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Company and its Subsidiaries (i)&nbsp;are in compliance
with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient
air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened
releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental
Laws</U>&rdquo;); (ii)&nbsp;have received all permits licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or
approval where in each clause (i), (ii)&nbsp;and (iii), the failure to so comply could be reasonably expected to have, individually or
in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
to Registration Statement</U>. The Company has delivered, or will as promptly as practicable deliver or make available, to the Underwriters
complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part
thereof, and conformed copies of the Registration Statement (without exhibits), the Preliminary Prospectus, the Prospectus and any Prospectus
Supplement, as amended or supplemented, in such quantities and at such places as an Underwriter reasonably requests. Neither the Company
nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material
in connection with the offering and sale of the Public Securities other than the Preliminary Prospectus, the Prospectus, any Prospectus
Supplement, the Registration Statement, and copies of the documents incorporated by reference therein. The Company shall not file any
such amendment or supplement to which the Representative shall reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Federal
Securities Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance</U>.
During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its reasonable best efforts
to comply with all requirements imposed upon it by the Securities Act and the rules&nbsp;and regulations thereunder and the Exchange Act
and the rules&nbsp;and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales of
or dealings in the Public Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating
to the Public Securities is required to be delivered under the Securities Act, any event shall have occurred as a result of which, in
the opinion of counsel for the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to
comply with the Securities Act, the Company will notify the Underwriters promptly and prepare and file with the Commission, subject to
Section&nbsp;4.1 hereof, an appropriate amendment or supplement in accordance with Section&nbsp;10 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Filing
of Final Prospectus</U>. The Company will file the Prospectus (in form and substance reasonably satisfactory to the Representative) with
the Commission pursuant to the requirements of Rule&nbsp;424.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exchange
Act Registration</U>. For a period of three years from the Execution Date: (i)&nbsp;the Company will use its reasonable best efforts to
maintain the registration of the Common Stock under the Exchange Act; and (ii)&nbsp;the Company will not deregister the Common Stock under
the Exchange Act without the prior written consent of the Representative, subject to the exercise of its fiduciary duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Free
Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating to the Public Securities
that would constitute an issuer free writing prospectus, as defined in Rule&nbsp;433 of the rules&nbsp;and regulations under the Securities
Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative is herein
referred to as a <B>&ldquo;</B><U>Permitted Free Writing Prospectus</U>.&rdquo; The Company represents that it will treat each Permitted
Free Writing Prospectus as an &ldquo;issuer free writing prospectus&rdquo; as defined in rule&nbsp;and regulations under the Securities
Act, and has complied and will comply with the applicable requirements of Rule&nbsp;433 of the Securities Act, including timely Commission
filing where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
to the Underwriters of Prospectuses</U>. The Company will deliver to the Underwriters, without charge, from time to time during the period
when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies of each Prospectus
as the Underwriters may reasonably request and, as soon as the Registration Statement or any amendment or supplement thereto becomes effective,
deliver to the Representative, if requested, two original executed Registration Statements, including exhibits, and all post-effective
amendments thereto and copies of all exhibits filed therewith or incorporated therein by reference and all original executed consents
of certified experts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effectiveness
and Events Requiring Notice to the Underwriters</U>. The Company will use its reasonable best efforts to cause the Registration Statement
to remain effective with a current prospectus until the later of nine (9)&nbsp;months from the Execution Date and the date on which the
Warrants are no longer outstanding, and will notify the Underwriters and holders of the Warrants promptly and confirm the notice in writing:
(i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of the issuance by the Commission of
any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&nbsp;of the issuance by any state securities
commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction
or of the initiation, or the threatening, of any proceeding for that purpose; (iv)&nbsp;of the mailing and delivery to the Commission
for filing of any amendment or supplement to the Registration Statement or Prospectus, provided that the filing of an amendment or supplement
to the Registration Statement on the SEC&rsquo;s EDGAR system shall be deemed to be such notification; (v)&nbsp;of the receipt of any
comments or request for any additional information from the Commission; and (vi)&nbsp;of the happening of any event during the period
described in this Section&nbsp;4.4 that, in the judgment of the Company, causes the Registration Statement or the Prospectus, as the case
may be, to include an untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter
a stop order or suspend such qualification at any time, the Company will make every reasonable effort to obtain promptly the lifting of
such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses
of the Offering</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General
Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and each Option Closing Date, if any,
to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (a)&nbsp;all filing fees and communication expenses relating to the registration of the Public Securities
to be sold in the Offering (including the Option Securities) with the Commission; (b)&nbsp;all FINRA Public Offering Filing System fees
associated with the review of the Offering by FINRA; (c)&nbsp;all fees and expenses relating to the listing of such Closing Shares, Option
Shares and Warrant Shares on the Trading Market and such other stock exchanges as the Company and the Representative together determine;
(d)&nbsp;all fees, expenses and disbursements relating to the registration or qualification of such Securities under the &ldquo;blue sky&rdquo;
securities laws of such states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation,
all filing and registration fees, and the fees and expenses of Blue Sky counsel); (e)&nbsp;the costs of all mailing and printing of the
underwriting documents (including, without limitation, the Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem
necessary; (f)&nbsp;the costs and expenses of the Company&rsquo;s public relations firm; (g)&nbsp;the costs of preparing, printing and
delivering the Public Securities; (h)&nbsp;fees and expenses of the Transfer Agent for the Public Securities (including, without limitation,
any fees required for same-day processing of any instruction letter delivered by the Company and fees and expenses pursuant to the Warrant
Agency Agreement); (i)&nbsp;stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the
Underwriters; (j)&nbsp;the fees and expenses of the Company&rsquo;s accountants; (k)&nbsp;the fees and expenses of the Company&rsquo;s
legal counsel and other agents and representatives; (l)&nbsp;the Underwriters&rsquo; costs of mailing prospectuses to prospective investors;
(m)&nbsp;the costs associated with advertising the Offering in the national editions of the Wall Street Journal and New York Times after
the Closing Date. The Underwriters may also deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or
each Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses
of the Representative</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section&nbsp;4.5(a), on the
Closing Date it will pay to the Representative all reasonable and documented, out-of-pocket expenses incurred, including travel, databases,
fees and disbursements of legal counsel, and of other consultants and advisors not to exceed $155,000 without the Company&rsquo;s prior
consent by deduction from the proceeds of the Offering contemplated herein. For the avoidance of doubt, the maximum amount of expenses
to be incurred by the Representative in connection with the Offering shall be $155,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Application
of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application
described under the caption &ldquo;Use of Proceeds&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Earnings Statements to Security Holders</U>. The Company will make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement (which need
not be certified by independent public or independent certified public accountants unless required by the Securities Act or the Rules&nbsp;and
Regulations under the Securities Act, but which shall satisfy the provisions of Rule&nbsp;158(a)&nbsp;under Section&nbsp;11(a)&nbsp;of
the Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stabilization</U>.
Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Internal
Controls</U>. Subject to the material weaknesses described in the SEC Reports, the Company will maintain a system of internal accounting
controls sufficient to provide reasonable assurances that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general
or specific authorization; (ii)&nbsp;transactions are recorded as necessary in order to permit preparation of financial statements in
accordance with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accountants</U>.
The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period of at least three
years after the Execution Date. The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>FINRA</U>.
The Company shall advise the Underwriters (who shall make an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder
of the Company becomes an affiliate or associated person of an Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely contractual
and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates or any selected dealer
shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in
connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding anything in this Agreement to
the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering that are not
limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters for the shares
and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial interests. The Company
hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with
respect to any breach or alleged breach of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance
of the Warrant Shares or if the Warrant is exercised via cashless exercise at a time when such Warrant Shares would be eligible for resale
under, and in accordance with, Rule&nbsp;144, the Warrant Shares issued pursuant to any such exercise shall be issued free of all restrictive
legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the
sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale of the Warrant Shares, the Company shall
promptly notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly
notify such holders when the registration statement is effective again and available for the sale of the Warrant Shares (it being understood
and agreed that the foregoing shall not limit the ability of the Company to issue, or any holder thereof to sell, any of the Warrant Shares
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as board members
and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated thereunder
and with the listing requirements of the Trading Market and (ii)&nbsp;if applicable, at least one member of the Board of Directors qualifies
as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules&nbsp;promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Laws Disclosure; Publicity</U>. At the request of the Representative, by 9:15 a.m.&nbsp;(New York City time) on the date hereof, the Company
shall issue a press release disclosing the material terms of the Offering. The Company and the Representative shall consult with each
other in issuing any other press releases with respect to the Offering, and neither the Company nor any Underwriter shall issue any such
press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release
of such Underwriter, or without the prior consent of such Underwriter, with respect to any press release of the Company, which consent
shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. The Company will not issue press releases
or engage in any other publicity, without the Representative&rsquo;s prior written consent, for a period ending at 5:00 p.m.&nbsp;(New
York City time) on the first business day following the 45th day following the Closing Date, other than normal and customary releases
issued in the ordinary course of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Underwriter
of the Public Securities is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares
and Option Shares pursuant to this Agreement and a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue the Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing
of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all
of the Closing Shares, Option Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Closing Shares,
Option Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded
on any other Trading Market, it will then include in such application all of the Closing Shares, Option Shares and Warrant Shares, and
will take such other action as is necessary to cause all of the Closing Shares, Option Shares and Warrant Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing
and trading of its Common Stock on a Trading Market and will comply in all material respects with the Company&rsquo;s reporting, filing
and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility of the Common
Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
the date hereof until seventy five (75) days following the Closing Date, neither the Company nor any Subsidiary shall issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or file
any registration statement or amendment or supplement thereto, other than the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
the date hereof until one hundred eighty (180) days following the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the
Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other
price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or effects
a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;,
whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually
been issued and regardless of whether such agreement is subsequently canceled; provided however, that after sixty (60) days following
the Closing Date, the Company&rsquo;s issuance of shares of Common Stock pursuant to an at-the-market offering facility with the Representative
shall not be deemed a Variable Rate Transaction hereunder. Any Underwriter shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing, this Section&nbsp;4.19 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Research
Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments, if any, are required
to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and
that such Underwriter&rsquo;s research analysts may hold and make statements or investment recommendations and/or publish research reports
with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases,
to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of
interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be
different from or inconsistent with the views or advice communicated to the Company by such Underwriter&rsquo;s investment banking divisions.
The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable
securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or
equity securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Prohibition
Regarding Existing Securities</U>. From the date hereof until one hundred eighty (180) days following the Closing Date, the Company shall
be prohibited from issuing any securities upon the exercise, exchange or conversion of any securities outstanding as of the date hereof
other than pursuant to such security&rsquo;s terms and exercise or conversion prices as in effect as of the date hereof, including, without
limitation, effecting or entering into an agreement to effect any security inducement, exchange or similar transaction with respect to
any and all securities issued and outstanding as of the date hereof in order to (i)&nbsp;decrease the exercise price, exchange price or
conversion price of any such securities or (ii)&nbsp;issue additional securities or increase the number of such securities or to modify
or extend the terms of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFAULT BY UNDERWRITERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
on the Closing Date or any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the Closing
Securities or Option </FONT>Securities, as the case may be, which such Underwriter has agreed to purchase and pay for on such date (otherwise
than by reason of any default on the part of the Company), the Representative, or if the Representative is the defaulting Underwriter,
the non-defaulting Underwriters, shall use their reasonable efforts to procure within 36 hours thereafter one or more of the other Underwriters,
or any others, to purchase from the Company such amounts as may be agreed upon and upon the terms set forth herein, the Closing Securities
or Option Securities, as the case may be, which the defaulting Underwriter or Underwriters failed to purchase. If during such 36 hours
the Representative shall not have procured such other Underwriters, or any others, to purchase the Closing Securities or Option Securities,
as the case may be, agreed to be purchased by the defaulting Underwriter or Underwriters, then (a)&nbsp;if the aggregate number of Closing
Securities or Option Securities, as the case may be, with respect to which such default shall occur does not exceed 10% of the Closing
Securities or Option Securities, as the case may be, covered hereby, the other Underwriters shall be obligated, severally, in proportion
to the respective numbers of Closing Securities or Option Securities, as the case may be, which they are obligated to purchase hereunder,
to purchase the Closing Securities or Option Securities, as the case may be, which such defaulting Underwriter or Underwriters failed
to purchase, or (b)&nbsp;if the aggregate number of Closing Securities or Option Securities, as the case may be, with respect to which
such default shall occur exceeds 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the Company or
the Representative will have the right to terminate this Agreement without liability on the part of the non-defaulting Underwriters or
of the Company except to the extent provided in Article&nbsp;VI hereof. In the event of a default by any Underwriter or Underwriters,
as set forth in this Article&nbsp;V, the applicable Closing Date may be postponed for such period, not exceeding seven days, as the Representative,
or if the Representative is the defaulting Underwriter, the non-defaulting Underwriters, may determine in order that the required changes
in the Prospectus or in any other documents or arrangements may be effected. The term &ldquo;Underwriter&rdquo; includes any Person substituted
for a defaulting Underwriter. Any action taken under this Section&nbsp;shall not relieve any defaulting Underwriter from liability in
respect of any default of such Underwriter under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VI.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
of the Underwriters</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Underwriters,
and each dealer selected by each Underwriter that participates in the offer and sale of the Public Securities (each a &ldquo;<U>Selected
Dealer</U>&rdquo;) and each of their respective directors, officers and employees and each Person, if any, who controls such Underwriter
or any Selected Dealer (&ldquo;<U>Controlling Person</U>&rdquo;) within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such Underwriter and any
third party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute
or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue
statement of a material fact contained in (i)&nbsp;any Preliminary Prospectus, if any, the Registration Statement or the Prospectus (as
from time to time each may be amended and supplemented); (ii)&nbsp;any materials or information provided to investors by, or with the
approval of, the Company in connection with the marketing of the offering of the Public Securities, including any &ldquo;road show&rdquo;
or investor presentations made to investors by the Company (whether in person or electronically); or (iii)&nbsp;any application or other
document or written communication (in this Article&nbsp;VI, collectively called &ldquo;<U>application</U>&rdquo;) executed by the Company
or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities under the securities
laws thereof or filed with the Commission, any state securities commission or agency, Trading Market or any securities exchange; or the
omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon and
in conformity with written information furnished to the Company with respect to the applicable Underwriter by or on behalf of such Underwriter
expressly for use in any Preliminary Prospectus, if any, the Registration Statement or Prospectus, or any amendment or supplement thereto,
or in any application, as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made
in the Preliminary Prospectus, if any, the indemnity agreement contained in this Section&nbsp;6.1 shall not inure to the benefit of an
Underwriter to the extent that any loss, liability, claim, damage or expense of such Underwriter results from the fact that a copy of
the Prospectus was not given or sent to the Person asserting any such loss, liability, claim or damage at or prior to the written confirmation
of sale of the Public Securities to such Person as required by the Securities Act and the rules&nbsp;and regulations thereunder, and if
the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance
by the Company with its obligations under this Agreement. The Company agrees promptly to notify each Underwriter of the commencement of
any litigation or proceedings against the Company or any of its officers, directors or Controlling Persons in connection with the issue
and sale of the Public Securities or in connection with the Registration Statement, the Preliminary Prospectus or Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Procedure</U>.
If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity may be sought
against the Company pursuant to Section&nbsp;6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case may be, shall
promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including
the employment and fees of counsel (subject to the reasonable approval of such Underwriter or such Selected Dealer, as the case may be)
and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall have the right to employ its or their
own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter, such Selected Dealer
or Controlling Person unless (i)&nbsp;the employment of such counsel at the expense of the Company shall have been authorized in writing
by the Company in connection with the defense of such action, or (ii)&nbsp;the Company shall not have employed counsel to have charge
of the defense of such action, or (iii)&nbsp;such indemnified party or parties shall have reasonably concluded that there may be defenses
available to it or them which are different from or additional to those available to the Company (in which case the Company shall not
have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable
fees and expenses of not more than one additional firm of attorneys selected by such Underwriter (in addition to local counsel), Selected
Dealer and/or Controlling Person shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter,
Selected Dealer or Controlling Person shall assume the defense of such action as provided above, the Company shall have the right to approve
the terms of any settlement of such action which approval shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
of the Company</U>. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, its directors, officers
and employees and agents who control the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to such
Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made in any
Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or in any application,
in reliance upon, and in strict conformity with, written information furnished to the Company with respect to such Underwriter by or on
behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment
or supplement thereto or in any such application. In case any action shall be brought against the Company or any other Person so indemnified
based on any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or any application,
and in respect of which indemnity may be sought against such Underwriter, such Underwriter shall have the rights and duties given to the
Company, and the Company and each other Person so indemnified shall have the rights and duties given to such Underwriter by the provisions
of this Article&nbsp;VI. Notwithstanding the provisions of this Section&nbsp;6.3, no Underwriter shall be required to indemnify the Company
for any amount in excess of the underwriting discounts and commissions applicable to the Public Securities purchased by such Underwriter.
The Underwriters' obligations in this Section&nbsp;6.3 to indemnify the Company are several in proportion to their respective underwriting
obligations and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contribution
Rights</U>. In order to provide for just and equitable contribution under the Securities Act in any case in which (i)&nbsp;any Person
entitled to indemnification under this Article&nbsp;VI makes a claim for indemnification pursuant hereto but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article&nbsp;VI
provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act, the Exchange Act or otherwise may be required
on the part of any such Person in circumstances for which indemnification is provided under this Article&nbsp;VI, then, and in each such
case, the Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities, claims, damages
and expenses of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such
proportions that such Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing
on the cover page&nbsp;of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the
balance; provided, that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section,
each director, officer and employee of such Underwriter or the Company, as applicable, and each Person, if any, who controls such Underwriter
or the Company, as applicable, within the meaning of Section&nbsp;15 of the Securities Act shall have the same rights to contribution
as such Underwriter or the Company, as applicable. Notwithstanding the provisions of this Section&nbsp;6.4, no Underwriter shall be required
to contribute any amount in excess of the underwriting discounts and commissions applicable to the Public Securities purchased by such
Underwriter. The Underwriters' obligations in this Section&nbsp;6.4 to contribute are several in proportion to their respective underwriting
obligations and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contribution
Procedure</U>. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(&ldquo;<U>contributing party</U>&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify the
contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder.
In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative
of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to participate therein with the
notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking
contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written
consent of such contributing party. The contribution provisions contained in this Section&nbsp;6.4 are intended to supersede, to the extent
permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VII.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
Right</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)&nbsp;if any
domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the immediate future materially
disrupt, general securities markets in the United States; or (ii)&nbsp;if trading of the Common Stock on any Trading Market shall have
been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for
securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction, or (iii)&nbsp;if
the United States shall have become involved in a new war or an increase in major hostilities, or (iv)&nbsp;if a banking moratorium has
been declared by a New York State or federal authority, or (v)&nbsp;if a moratorium on foreign exchange trading has been declared which
materially adversely impacts the United States securities markets, or (vi)&nbsp;if the Company shall have sustained a material loss by
fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall
have been insured, will, in the Representative&rsquo;s opinion, make it inadvisable to proceed with the delivery of the Public Securities,
or (vii)&nbsp;if the Company is in material breach of any of its representations, warranties or covenants hereunder, or (viii)&nbsp;if
the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the
Company, or such adverse material change in general market conditions as in the Representative&rsquo;s judgment would make it impracticable
to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters for the sale
of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
In the event this Agreement shall be terminated pursuant to Section&nbsp;7.1(a), within the time specified herein or any extensions thereof
pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable reasonable and documented
out of pocket expenses related to the transactions contemplated herein then due and payable, including the fees and disbursements of EGS
up to $35,000.00 (<U>provided</U>, <U>however</U>, that such expense cap in no way limits or impairs the indemnification and contribution
provisions of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether
or not this Agreement is otherwise carried out, the provisions of Article&nbsp;VI shall not be in any way effected by such election or
termination or failure to carry out the terms of this Agreement or any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus, the Prospectus
and any Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and
supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been
merged into such documents, exhibits and schedules. Notwithstanding anything herein to the contrary, the Investment Banking Agreement,
dated March&nbsp;4, 2025, as amended on May&nbsp;12, 2025, December&nbsp;22, 2025 and January&nbsp;5, 2026 (the &ldquo;<U>Engagement Agreement</U>&rdquo;),
by and between the Company and the Representative, shall continue to be effective and the terms therein, including, without limitation,
Section&nbsp;4(c)&nbsp;with respect to any future offerings, shall continue to survive and be enforceable by the Representative in accordance
with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms
of this Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
e-mail attachment at the email address set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York City
time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via
e-mail attachment at the e-mail address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or
later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the date
of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and the Representative. No waiver of any default with respect to any provision, condition or
requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an
Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Article&nbsp;VI, the prevailing party in such Action or Proceeding shall be reimbursed by the other party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the Option Closing, if any, and the delivery of the
Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Underwriters
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If the last or appointed day for
the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be
taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT
PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY RIGHT TO TRIAL BY JURY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly sets forth the understanding
between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall
constitute a binding agreement among the Company and the several Underwriters in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">METAVIA INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 47%"> <FONT STYLE="font-size: 10pt">/s/ Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President, Chief Executive Officer and Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">545 Concord Avenue, Suite&nbsp;210<BR>
Cambridge, Massachusetts 02138</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Hyung Heon Kim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Honigman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">650 Trade Centre Way, Suite&nbsp;200,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kalamazoo, Michigan 49002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Phillip Torrence,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LADENBURG THALMANN&nbsp;&amp; CO. INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As the Representative of the several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriters listed on Schedule I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Nicholas Stergis</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">Nicholas Stergis</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Director</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">640 Fifth Avenue, 4<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ellenoff Grossman&nbsp;&amp; Schole LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1345 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Michael Nertney,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Schedule
of Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Closing <BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Pre-<BR> Funded<BR> Warrants</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Closing <BR> Series&nbsp;C <BR> Warrants</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Closing <BR> Series&nbsp;D<BR> Warrants</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Closing <BR> Purchase<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">614,840</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,998,704</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,920,316</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,920,316</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,370,988.80</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">614,840</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,998,704</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,920,316</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,920,316</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,370,988.80</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Schedule
of Lock-up Parties</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Lock-Up Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Pre-Funded Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Series&nbsp;C Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Series&nbsp;D Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Warrant Agency Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Officer Certificate</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;G</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Form&nbsp;of
Secretary Certificate</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm263364d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>METAVIA
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Warrant Shares: 1,998,704</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%">Initial Exercise Date: January&nbsp;16, 2026</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: 64132R 131</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISIN: US64132R1317</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, <FONT STYLE="font-variant: small-caps">CEDE&nbsp;&amp;
CO.,</FONT> or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and until this Warrant is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from MetaVia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to 1,998,704 shares (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant shall initially be issued and maintained in the form of a security
held in book-entry form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered
holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of
the Warrant Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;1</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices) <FONT STYLE="background-color: white">(the &ldquo;<U>Pink Open Market</U>&rdquo;)</FONT>,
the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-292581).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 1110 Centre Point
Curve, Suite&nbsp;101, Mendota Heights, Minnesota 55120-4100, Attn: Corporate Actions, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the underwriting agreement, dated as of January&nbsp;15, 2026, between the Company and Ladenburg Thalmann&nbsp;&amp;
Co. Inc. as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with
its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">p)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">q)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agent</U>&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">r)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Pre-Funded Common Stock Purchase Warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;2</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise of
Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in
the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing in this Section&nbsp;2(a), a Holder whose interest in this Warrant is a beneficial interest in certificate(s)&nbsp;representing
this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section&nbsp;2(a)&nbsp;by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, by means of a &ldquo;cashless exercise&rdquo; in which the Holder
shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof, or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any
position contrary to this Section&nbsp;2(c)<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i)&nbsp;one Trading Day after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for
each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00 p.m.&nbsp;(New
York City time) on the Trading Day immediately prior to the Initial Exercise Date, which may be delivered at any time after the time of
execution of the Underwriting Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New
York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share
Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice (including
by email) to the Company at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date and the Holder has paid any required Exercise Price for the portion
of this Warrant being exercised on or prior to such Warrant Share Delivery Date (or utilized cashless exercise, if available), and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the
amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including customary brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order
giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto as <U>Exhibit&nbsp;B</U> duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not
be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;3</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall notify the Company that it is not entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) (with such Beneficial Ownership Limitation determined
by the Holder) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as the Holder
notifies the Company that its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution; <U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall notify the Company that it is not entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) (with such
Beneficial Ownership Limitation determined by the Holder) and the portion of such Distribution shall be held in abeyance for the benefit
of the Holder until such time, if ever, as the Holder notifies the Company that its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation; and <U>provided</U>, <U>further</U>, <U>however</U>, that Holder shall not be entitled to participate
in any such Distribution to the extent that such Distribution constitutes a Fundamental Transaction and the provisions of Section&nbsp;3(d)&nbsp;below
are applicable to such Distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50%
of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding
shares of Common Stock or greater than 50% of the voting power of the common equity of the Company, except, in each case of (i)&nbsp;through
(v), actions taken solely in connection with any internal reorganization (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;4</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names
and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a),
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants
in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or
exchanges shall be dated the Initial Exercise Date of this Warrant and shall be identical with this Warrant except as to the number of
Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the
 &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;5</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at MetaVia Inc., 545 Concord Avenue, Suite&nbsp;210, Cambridge, Massachusetts 02138, Attention: Chief Executive Officer,
email address: hhkim@metaviatx.com, or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the
e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on
a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the
party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. Notwithstanding any other provision of this Warrant, as to any Warrant not held in certificated
form, where this Warrant provides for notice of any event to a Holder, such notice shall be sufficiently given if given to DTC (or any
successor depository) pursuant to the procedures of DTC (or such successor depository).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and assigns of the Company and the successors and assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Other than Section&nbsp;2(e)&nbsp;which may not be amended, this Warrant may be modified or amended or the provisions hereof waived with
the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject
to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency
Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>MetaVia
    Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Hyung Heon Kim</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-size: 10pt">Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>equinitI TRUST company, llc</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Michael Legregin</I> &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Legregin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>MetaVia
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted, the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c)&nbsp;of the Warrant, to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c)&nbsp;of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 18%">Name of Investing Entity:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 82%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: italic 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 5%">Date:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 95%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: _____________________________ __, _______________________</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 36%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>tm263364d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES C COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>METAVIA
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Warrant Shares: 4,508,361</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%">Initial Exercise Date: January&nbsp;16, 2026</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: 64132R 602</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISIN: US64132R6027</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES C COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, <FONT STYLE="font-variant: small-caps">CEDE&nbsp;&amp;
Co., </FONT>or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m.&nbsp;(New York City time) on January&nbsp;16, 2031 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from MetaVia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to 4,508,361 shares (as
subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant shall initially be issued and maintained
in the form of a security held in book-entry form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially
be the sole registered holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant
to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;1</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices) <FONT STYLE="background-color: white">(the &ldquo;<U>Pink Open Market</U>&rdquo;)</FONT>,
the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-292581).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 1110 Centre Point
Curve, Suite&nbsp;101, Mendota Heights, Minnesota 55120-4100, Attn: Corporate Actions, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">p)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">q)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">r)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agent</U>&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">s)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Series&nbsp;C Common Stock Purchase Warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;2</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type
of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing in this Section&nbsp;2(a), a Holder whose interest in this Warrant is a beneficial interest in certificate(s)&nbsp;representing
this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section&nbsp;2(a)&nbsp;by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $3.10, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify"> as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof, or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any
position contrary to this Section&nbsp;2(c)<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i)&nbsp;one Trading Day after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for
each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice (including
by email) to the Company at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date and the Holder has paid any required Exercise Price for the portion
of this Warrant being exercised on or prior to such Warrant Share Delivery Date (or utilized cashless exercise, if available), and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the
amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including customary brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order
giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto as <U>Exhibit&nbsp;B</U> duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not
be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;3</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall notify the Company that it is not entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) (with such Beneficial Ownership Limitation determined
by the Holder) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as the Holder
notifies the Company that its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution; <U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall notify the Company that it is not entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) (with such
Beneficial Ownership Limitation determined by the Holder) and the portion of such Distribution shall be held in abeyance for the benefit
of the Holder until such time, if ever, as the Holder notifies the Company that its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation; and <U>provided</U>, <U>further</U>, <U>however</U>, that Holder shall not be entitled to participate
in any such Distribution to the extent that such Distribution constitutes a Fundamental Transaction and the provisions of Section&nbsp;3(d)&nbsp;below
are applicable to such Distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50%
of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding
shares of Common Stock or greater than 50% of the voting power of the common equity of the Company, except, in each case of (i)&nbsp;through
(v), actions taken solely in connection with any internal reorganization (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by
paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this
Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not
within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the 100 day volatility obtained
from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the
public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction, (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black
Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i)&nbsp;five
Business Days of the Holder&rsquo;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voluntary
Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;4</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names
and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a),
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants
in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or
exchanges shall be dated the Initial Exercise Date of this Warrant and shall be identical with this Warrant except as to the number of
Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the
 &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;5</U>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at MetaVia Inc., 545 Concord Avenue, Suite&nbsp;210, Cambridge, Massachusetts 02138, Attention: Chief Executive Officer,
email address: hhkim@metaviatx.com, or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the
e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on
a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the
party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. Notwithstanding any other provision of this Warrant, as to any Warrant not held in certificated
form, where this Warrant provides for notice of any event to a Holder, such notice shall be sufficiently given if given to DTC (or any
successor depository) pursuant to the procedures of DTC (or such successor depository).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and assigns of the Company and the successors and assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Other than Section&nbsp;2(e)&nbsp;which may not be amended, this Warrant may be modified or amended or the provisions hereof waived with
the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject
to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency
Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>MetaVia Inc.</B></FONT> &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><I>/s/ Hyung Heon Kim</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 42%">Hyung Heon Kim</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President and Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>equinitI TRUST company, llc</B></FONT> &nbsp; &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><I>/s/ Michael Legregin</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">Name:</TD>
    <TD STYLE="text-align: left; width: 42%">Michael Legregin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Senior Vice President</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>MetaVia
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted, the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c)&nbsp;of the Warrant, to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c)&nbsp;of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 82%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 65%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 95%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: _____________________________ __, _______________________</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 36%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>tm263364d1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES D COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>METAVIA
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Warrant Shares: 4,508,361</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%">Initial Exercise Date: January&nbsp;16, 2026</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: 64132R 149</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ISIN: </FONT>US64132R1499</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS SERIES D COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, <FONT STYLE="font-variant: small-caps">CEDE&nbsp;&amp;
CO.,</FONT> or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m.&nbsp;(New York City time) on January&nbsp;16, 2028 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from MetaVia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to 4,508,361 shares (as
subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant shall initially be issued and maintained
in the form of a security held in book-entry form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially
be the sole registered holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant
to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;1</U></FONT>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices) <FONT STYLE="background-color: white">(the &ldquo;<U>Pink Open Market</U>&rdquo;)</FONT>,
the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-292581).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 1110 Centre Point
Curve, Suite&nbsp;101, Mendota Heights, Minnesota 55120-4100, Attn: Corporate Actions, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Agent</U>&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Series&nbsp;D Common Stock Purchase Warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;2</U></FONT>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type
of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing in this Section&nbsp;2(a), a Holder whose interest in this Warrant is a beneficial interest in certificate(s)&nbsp;representing
this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section&nbsp;2(a)&nbsp;by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $3.10, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal
to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof, or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: center; width: 0.25in">=</TD>
                                                                                <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any
position contrary to this Section&nbsp;2(c)<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i)&nbsp;one Trading Day after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;one Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for
each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice (including
by email) to the Company at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date and the Holder has paid any required Exercise Price for the portion
of this Warrant being exercised on or prior to such Warrant Share Delivery Date (or utilized cashless exercise, if available), and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the
amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including customary brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order
giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto as <U>Exhibit&nbsp;B</U> duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written request of a Holder, the Company shall within one Trading Day confirm in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not
be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Call
Provision</U>. Subject to the provisions of Section&nbsp;2(e)&nbsp;and this Section&nbsp;2(f), if, after the Initial Exercise Date and
after the release by the Company of a positive data readout for its Phase 1b Part&nbsp;III clinical trial for its product candidate DA-1726
via a widely disseminated press release (the date in which the Company releases such results, the &ldquo;<U>Milestone Event Date</U>&rdquo;),
(i)&nbsp;the VWAP for each of 20 consecutive Trading Days (the &ldquo;<U>Measurement Period</U>,&rdquo; which 20 consecutive Trading Day
period shall not have commenced until after the Milestone Event Date) exceeds $4.65 (subject to adjustment for forward and reverse stock
splits, recapitalizations, stock dividends and the like after the Initial Exercise Date), (ii)&nbsp;the average daily dollar volume for
such Measurement Period exceeds $500,000 per Trading Day and (iii)&nbsp;the Holder is not in possession of any information that constitutes,
or might constitute, material non-public information which was provided by the Company, any of its Subsidiaries, or any of their officers,
directors, employees, agents or Affiliates, then the Company may, within one (1)&nbsp;Trading Day of the end of such Measurement Period,
call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet been delivered (such right, a &ldquo;<U>Call</U>&rdquo;)
for consideration equal to $0.001 per Warrant Share. To exercise this right, the Company must deliver to the Holder an irrevocable written
notice (a &ldquo;<U>Call Notice</U>&rdquo;), indicating therein the portion of unexercised portion of this Warrant to which such notice
applies. If the conditions set forth below for such Call are satisfied for the period from the date of the Call Notice through and including
the Call Date (as defined below), then any portion of this Warrant subject to such Call Notice for which a Notice of Exercise shall not
have been received by the Call Date will be cancelled at 6:30 p.m.&nbsp;(New York City time) on the tenth Trading Day after the date the
Call Notice is received by the Holder (such date and time, the &ldquo;<U>Call Date</U>&rdquo;). Any unexercised portion of this Warrant
to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company covenants and agrees
that it will honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice that are tendered through 6:30 p.m.&nbsp;(New
York City time) on the Call Date. The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than
all of the Warrants shall first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining
Warrant Shares available for purchase under this Warrant. For example, if (A)&nbsp;this Warrant then permits the Holder to acquire 100
Warrant Shares, (B)&nbsp;a Call Notice pertains to 75 Warrant Shares, and (C)&nbsp;prior to 6:30 p.m.&nbsp;(New York City time) on the
Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x)&nbsp;on the Call Date the right under this
Warrant to acquire 25 Warrant Shares will be automatically cancelled, (y)&nbsp;the Company, in the time and manner required under this
Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the exercises following receipt of the Call Notice,
and (z)&nbsp;the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to adjustment as herein
provided and subject to subsequent Call Notices). Subject again to the provisions of this Section&nbsp;2(f)&nbsp;(including the satisfaction
of the conditions during the time periods set forth herein), the Company may deliver subsequent Call Notices for any portion of this Warrant
for which the Holder shall not have delivered a Notice of Exercise. Notwithstanding anything to the contrary set forth in this Warrant,
the Company may not deliver a Call Notice or require the cancellation of this Warrant (and any such Call Notice shall be void), unless,
from the beginning of the Measurement Period through the Call Date, (1)&nbsp;the Company shall have honored in accordance with the terms
of this Warrant all Notices of Exercise delivered by 6:30 p.m.&nbsp;(New York City time) on the Call Date, (2)&nbsp;a registration statement
shall be effective as to all Warrant Shares and the prospectus thereunder available for use by the Company for the sale of all such Warrant
Shares to the Holder, (3)&nbsp;the Common Stock shall be listed or quoted for trading on the Trading Market, (4)&nbsp;there is a sufficient
number of authorized shares of Common Stock for issuance of all Warrant Shares, (5)&nbsp;the issuance of all Warrant Shares subject to
a Call Notice shall not cause a breach of any provision of Section&nbsp;2(e)&nbsp;herein, (6)&nbsp;the Company shall have paid all liquidated
damages and other amounts owing to the Holder in respect of the Warrants, (7)&nbsp;there has been no public announcement of a pending
or proposed Fundamental Transaction that has not been consummated and (8)&nbsp;the Holder is not in possession of any information provided
by the Company, any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that constitutes, or may
constitute, material non-public information. The Company&rsquo;s right to call the Warrants under this Section&nbsp;2(f)&nbsp;shall be
exercised ratably among the Holders based on each Holder&rsquo;s initial purchase of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;3</U></FONT>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall notify the Company that it is not entitled to participate in such Purchase Right to such extent (or
beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) (with such Beneficial Ownership
Limitation determined by the Holder) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as the Holder notifies the Company that its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution; <U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall notify the Company that it is not entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) (with such
Beneficial Ownership Limitation determined by the Holder) and the portion of such Distribution shall be held in abeyance for the benefit
of the Holder until such time, if ever, as the Holder notifies the Company that its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation; and <U>provided</U>, <U>further</U>, <U>however</U>, that Holder shall not be entitled to participate
in any such Distribution to the extent that such Distribution constitutes a Fundamental Transaction and the provisions of Section&nbsp;3(d)&nbsp;below
are applicable to such Distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the assets of the Company in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50%
of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding
shares of Common Stock or greater than 50% of the voting power of the common equity of the Company, except, in each case of (i)&nbsp;through
(v), actions taken solely in connection with any internal reorganization (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by
paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this
Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not
within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity
may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the 100 day volatility obtained
from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the
public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction, (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black
Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i)&nbsp;five
Business Days of the Holder&rsquo;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voluntary
Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;4</U></FONT>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names
and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a),
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants
in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or
exchanges shall be dated the Initial Exercise Date of this Warrant and shall be identical with this Warrant except as to the number of
Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the
 &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;5</U></FONT>.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at MetaVia Inc., 545 Concord Avenue, Suite&nbsp;210, Cambridge, Massachusetts 02138, Attention: Chief Executive Officer,
email address: hhkim@metaviatx.com, or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the
e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on
a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the
party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. Notwithstanding any other provision of this Warrant, as to any Warrant not held in certificated
form, where this Warrant provides for notice of any event to a Holder, such notice shall be sufficiently given if given to DTC (or any
successor depository) pursuant to the procedures of DTC (or such successor depository).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and assigns of the Company and the successors and assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Other than Section&nbsp;2(e)&nbsp;which may not be amended, this Warrant may be modified or amended or the provisions hereof waived with
the written consent of the Company, on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject
to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency
Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>MetaVia
    Inc.</B></FONT> <FONT STYLE="font-size: 10pt">&nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Hyung Heon Kim</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-size: 10pt">Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>equinitI
    TRUST company, llc</B></FONT> <FONT STYLE="font-size: 10pt">&nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Michael Legregin</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-size: 10pt">Michael Legregin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="text-transform: uppercase"><B>MetaVia
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted, the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c)&nbsp;of the Warrant, to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c)&nbsp;of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 82%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 65%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 95%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: _____________________________ __, _______________________</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 36%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>tm263364d1_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>METAVIA INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EQUINITI TRUST COMPANY, LLC</B>,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">as Warrant Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrant Agency Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of January&nbsp;16, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WARRANT AGENCY AGREEMENT,
dated as of January&nbsp;16, 2026 (&ldquo;<U>Agreement</U>&rdquo;), between MetaVia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and Equiniti Trust Company, LLC (the &ldquo;<U>Warrant Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to a registered
offering (the &ldquo;<U>Offering</U>&rdquo;), the Company issued 1,006,870 shares of common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;), pre-funded warrants to purchase 1,998,704 shares of Common Stock at an exercise price of $0.001 per pre-funded warrant
(the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;), Series&nbsp;C common stock warrants to purchase 4,508,361 shares of Common Stock at an
exercise price of $3.10 per warrant (the &ldquo;<U>Series&nbsp;C Warrants</U>&rdquo;), and Series&nbsp;D common stock warrants to purchase
4,508,361 shares of Common Stock at an exercise price of $3.10 per warrant (the &ldquo;<U>Series&nbsp;D Warrants</U>&rdquo;, collectively
with the Pre-Funded Warrants and the Series&nbsp;C Warrants, the &ldquo;<U>Warrants</U>&rdquo;, and the shares of Common Stock underlying
the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;), pursuant to an underwriting agreement, dated as of January&nbsp;15, 2026, by and
between the Company and Ladenburg Thalmann&nbsp;&amp; Co. Inc. (the &ldquo;<U>Underwriting Agreement</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, upon the terms and
subject to the conditions hereinafter set forth and pursuant to an effective registration statement on Form&nbsp;S-1, as amended (File
No.&nbsp;333-292581) (the &ldquo;<U>Registration Statement</U>&rdquo;), and the terms and conditions of the Warrant Certificate (as defined
below), the Company wishes to issue the Warrants in book entry form entitling the respective holders of the Warrants (the &ldquo;<U>Holders</U>,&rdquo;
which term shall include a Holder&rsquo;s transferees, successors and assigns and &ldquo;Holder&rdquo; shall include, if the Warrants
are held in &ldquo;street name,&rdquo; a Participant (as defined below) or a designee appointed by such Participant); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company wishes
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration,
transfer, exchange, exercise and replacement of the Warrants and, in the Warrant Agent&rsquo;s capacity as the Company&rsquo;s transfer
agent, the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Definitions</U>. For purposes of this Agreement, all capitalized terms not herein defined shall have the meanings hereby indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which the Nasdaq Stock Market is authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Close
of Business</U>&rdquo; on any given date means 5:00 p.m., New York City time, on such date; <U>provided</U>, <U>however</U>, that if such
date is not a Business Day it means 5:00 p.m., New York City time, on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Warrant
Certificate</U>&rdquo; means a certificate in substantially the form attached as <U>Exhibit&nbsp;1-A</U> hereto (as it relates to the
Pre-Funded Warrants), <U>Exhibit&nbsp;1-B</U> hereto (as it relates to the Series&nbsp;C Warrants) and <U>Exhibit&nbsp;1-C</U> hereto
(as it relates to the Series&nbsp;D Warrants), representing such number of Warrant Shares as is indicated therein, provided that any reference
to the delivery of a Warrant Certificate in this Agreement shall include delivery of a Definitive Certificate or a Global Warrant (each
as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other capitalized terms
used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Appointment
of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and conditions
hereof, and the Warrant Agent hereby accepts such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Global
Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrants shall be registered securities and shall be evidenced by a global warrant (the &ldquo;<U>Global Warrants</U>&rdquo;), in the
form of the Warrant Certificate, which shall be deposited with the Warrant Agent and registered in the name of Cede&nbsp;&amp; Co., a
nominee of The Depository Trust Company (the &ldquo;<U>DTC</U>&rdquo;), or as otherwise directed by the DTC. Ownership of beneficial interests
in the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i)&nbsp;the DTC
or its nominee for each Global Warrant or (ii)&nbsp;institutions that have accounts with the DTC (such institution, with respect to a
Warrant in its account, a &ldquo;<U>Participant</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the DTC subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant
Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer
necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the DTC to deliver
to the Warrant Agent for cancellation of each Global Warrant, and the Company shall instruct the Warrant Agent to deliver to each Holder
a Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate
Request Notice (as defined below). Upon written notice by a Holder to the Company and the Warrant Agent for the exchange of some or all
of such Holder&rsquo;s Global Warrants for a separate certificate in the form attached hereto as <U>Exhibit&nbsp;1-A, Exhibit&nbsp;1-B</U>,
or <U>Exhibit&nbsp;1-C</U>, as the case may be, (such separate certificate, a &ldquo;<U>Definitive Certificate</U>&rdquo;), evidencing
the same number of Warrants, which request shall be in the form attached hereto as <U>Exhibit&nbsp;2</U> (a &ldquo;<U>Warrant Certificate
Request Notice</U>&rdquo; and the date of delivery of such Warrant Certificate Request Notice by the Holder, the &ldquo;Warrant Certificate
Request Notice Date&rdquo; and the surrender by the Holder to the Warrant Agent of a number of Global Warrants for the same number of
Warrants evidenced by a Warrant Certificate, a &ldquo;<U>Warrant Exchange</U>&rdquo;), the Company and the Warrant Agent shall promptly
effect the Warrant Exchange and the Company shall promptly issue and deliver to the Holder a Definitive Certificate for such number of
Warrants in the name set forth in the Warrant Certificate Request Notice. Such Definitive Certificate shall be dated the Initial Exercise
Date of the Warrants, shall be manually executed by an authorized signatory of the Company, shall be in the form attached hereto as <U>Exhibit&nbsp;1-A</U>,
<U>Exhibit&nbsp;1-B</U>, or <U>Exhibit&nbsp;1-C</U>, as the case may be, and shall be reasonably acceptable in all respects to such Holder.
In connection with a Warrant Exchange, the Company agrees to deliver the Definitive Certificate to the Holder within ten (10)&nbsp;Business
Days of the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (&ldquo;<U>Warrant
Certificate Delivery Date</U>&rdquo;). If the Company fails for any reason to deliver to the Holder the Definitive Certificate subject
to the Warrant Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Definitive Certificate (based on the VWAP of the Common
Stock on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day after such Warrant Certificate Delivery
Date until such Definitive Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant
Exchange. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall
be deemed to be the holder of the Definitive Certificate and, notwithstanding anything to the contrary set forth herein, the Definitive
Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced by such Warrant Certificate
and the terms of this Agreement, other than Sections 3(c), 3(d)&nbsp;and 9 herein, shall not apply to the Warrants evidenced by the Definitive
Certificate. Notwithstanding anything herein to the contrary, the Company shall act as warrant agent with respect to any Definitive Certificate
requested and issued pursuant to this section. Notwithstanding anything to the contrary contained in this Agreement, in the event of inconsistency
between any provision in this Agreement and any provision in a Definitive Certificate, as it may from time to time be amended, the terms
of such Definitive Certificate shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
Holder of a Definitive Certificate (pursuant to a Warrant Exchange or otherwise) has the right to elect at any time or from time to time
a Global Warrants Exchange (as defined below) pursuant to a Global Warrants Request Notice (as defined below). Upon written notice by
a Holder to the Company for the exchange of some or all of such Holder&rsquo;s Warrants evidenced by a Definitive Certificate for a beneficial
interest in Global Warrants held in book-entry form through the DTC evidencing the same number of Warrants, which request shall be in
the form attached hereto as <U>Exhibit&nbsp;3</U> (a &ldquo;<U>Global Warrants Request Notice</U>&rdquo; and the date of delivery of such
Global Warrants Request Notice by the Holder, the &ldquo;<U>Global Warrants Request Notice Date</U>&rdquo; and the surrender upon delivery
by the Holder of the Warrants evidenced by Definitive Certificates for the same number of Warrants evidenced by a beneficial interest
in Global Warrants held in book-entry form through the DTC, a &ldquo;<U>Global Warrants Exchange</U>&rdquo;), the Company shall promptly
effect the Global Warrants Exchange and shall promptly direct the Warrant Agent to issue and deliver to the Holder Global Warrants for
such number of Warrants in the Global Warrants Request Notice, which beneficial interest in such Global Warrants shall be delivered by
the DTC&rsquo;s Deposit or Withdrawal at Custodian system to the Holder pursuant to the instructions in the Global Warrants Request Notice.
In connection with a Global Warrants Exchange, the Company shall direct the Warrant Agent to deliver the beneficial interest in such Global
Warrants to the Holder within ten (10)&nbsp;Business Days of the Global Warrants Request Notice pursuant to the delivery instructions
in the Global Warrant Request Notice (&ldquo;<U>Global Warrants Delivery Date</U>&rdquo;). If the Company fails for any reason to deliver
to the Holder Global Warrants subject to the Global Warrants Request Notice by the Global Warrants Delivery Date, the Company shall pay
to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Global Warrants
(based on the VWAP of the Common Stock on the Global Warrants Request Notice Date), $10 per Business Day for each Business Day after such
Global Warrants Delivery Date until such Global Warrants are delivered or, prior to delivery of such Global Warrants, the Holder rescinds
such Global Warrants Exchange. The Company covenants and agrees that, upon the date of delivery of the Global Warrants Request Notice,
the Holder shall be deemed to be the beneficial holder of such Global Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Form&nbsp;of
Warrant Certificates</U>. The Warrant Certificate, together with the form of election to purchase Common Stock (&ldquo;<U>Notice of Exercise</U>&rdquo;)
and the form of assignment to be printed on the reverse thereof, shall be substantially in the form attached hereto as <U>Exhibit&nbsp;1-A</U>,
<U>Exhibit&nbsp;1-B</U>, or <U>Exhibit&nbsp;1-C</U>, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Countersignature
and Registration</U>. The Global Warrant shall be executed on behalf of the Company by its Chief Executive Officer or Chief Financial
Officer, by electronic signature, and have affixed thereto the Company&rsquo;s seal thereof which shall be attested by the Secretary or
an Assistant Secretary of the Company, by electronic signature. In case any officer of the Company who shall have signed any of the Global
Warrant shall cease to be such officer of the Company before countersignature by the Warrant Agent and issuance and delivery by the Company,
such Global Warrant, nevertheless, may be countersigned by the Warrant Agent, issued and delivered with the same force and effect as though
the person who signed such Global Warrant had not ceased to be such officer of the Company; and any Global Warrant may be signed on behalf
of the Company by any person who, at the actual date of the execution of such Global Warrant, shall be a proper officer of the Company
to sign such Global Warrant, although at the date of the execution of this Agreement any such person was not such an officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Agent will keep
or cause to be kept, at one of its offices, or at the office of one of its agents, books for registration and transfer of the Global Warrants
issued hereunder. Such books shall show the names and addresses of the respective Holders of the Global Warrant, the number of warrants
evidenced on the face of each of such Global Warrant and the date of each of such Global Warrant. The Warrant Agent will create a special
account for the issuance of Global Warrants. The Company will keep or cause to be kept at one of its offices, books for the registration
and transfer of any Definitive Certificates issued hereunder and the Warrant Agent shall not have any obligation to keep books and records
with respect to any Warrants held in definitive form. Such Company books shall show the names and addresses of the respective Holders
of the Definitive Certificates, the number of warrants evidenced on the face of each such Definitive Certificate and the date of each
such Definitive Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer,
Split Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates</U>. With respect
to the Global Warrant, subject to the provisions of the Warrant Certificate and the last sentence of this first paragraph of Section&nbsp;6
and subject to applicable law, rules&nbsp;or regulations, or any &ldquo;stop transfer&rdquo; instructions the Company may give to the
Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close of Business on the Termination Date (as
such term is defined in the Warrant Certificate), any Global Warrant or Global Warrants may be transferred, split up, combined or exchanged
for another Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common Stock as the Global
Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring to transfer, split up, combine or exchange
any Global Warrant shall make such request in writing delivered to the Warrant Agent, and shall surrender the Global Warrant to be transferred,
split up, combined or exchanged at the principal office of the Warrant Agent. Any requested transfer of Warrants, whether in book-entry
form or certificate form, shall be accompanied by reasonable evidence of authority of the party making such request that may be required
by the Warrant Agent. Thereupon the Warrant Agent shall, subject to the last sentence of this first paragraph of Section&nbsp;6, countersign
and deliver to the Person entitled thereto a Global Warrant or Global Warrants, as the case may be, as so requested. The Company may require
payment from the Holder of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer,
split up, combination or exchange of Global Warrants. The Company shall compensate the Warrant Agent per the fee schedule mutually agreed
upon by the parties hereto and provided separately on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt by the Warrant
Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence
shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case
of loss, theft or destruction, of indemnity in customary form and amount (but, with respect to any Definitive Certificates, shall not
include the posting of any bond by the Holder), and satisfaction of any other reasonable requirements established by Section&nbsp;8-405
of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant Agent of all reasonable
expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Company
will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the Holder in lieu of the Warrant Certificate
so lost, stolen, destroyed or mutilated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Warrants; Exercise Price; Termination Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable as set forth in the
Warrant Certificate. Subject to the foregoing and to Section&nbsp;7(b)&nbsp;below, the Holder of a Warrant may exercise the Warrant in
whole or in part pursuant to Section&nbsp;2 of the Warrant Certificate. Subject to Section&nbsp;7(b)&nbsp;below, payment of the Exercise
Price (unless exercised via a cashless exercise) may be made, at the option of the Holder, by wire transfer or by certified or official
bank check in United States dollars, to the Warrant Agent at the principal office of the Warrant Agent or to the office of one of its
agents as may be designated by the Warrant Agent from time to time. In the case of the Holder of a Global Warrant, the Holder shall deliver
the executed Notice of Exercise and the payment of the Exercise Price as described herein. Notwithstanding any other provision in this
Agreement, a holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the
DTC (or another established clearing corporation performing similar functions), shall effect exercises by delivering to the DTC (or such
other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise
that are required by the DTC (or such other clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained
by the Warrant Agent in connection with the services provided under this Agreement will be in its name and that the Warrant Agent may
receive investment earnings in connection with the investment at Warrant Agent&rsquo;s risk and for its benefit of funds held in those
accounts from time to time. Neither the Company nor the Holders will receive interest on any deposits or Exercise Price. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. The Company hereby acknowledges and agrees that, with respect to a holder whose interest in a Global Warrant is
a beneficial interest in a Global Warrant held in book-entry form through the DTC (or another established clearing corporation performing
similar functions), upon delivery of irrevocable instructions to such holder&rsquo;s Participant to exercise such warrants, that solely
for purposes of Regulation SHO that such holder shall be deemed to have exercised such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
receipt of a Notice of Exercise for a cashless exercise, the Company will promptly calculate and transmit to the Warrant Agent the number
of Warrant Shares issuable in connection with such cashless exercise and deliver a copy of the Notice of Exercise to the Warrant Agent,
which shall issue such number of Warrant Shares in connection with such cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the exercise of the Warrant Certificate pursuant to the terms of Section&nbsp;2 of the Warrant Certificate, the Warrant Agent shall cause
the Warrant Shares underlying such Warrant Certificate or Global Warrant to be delivered to or upon the order of the Holder of such Warrant
Certificate or Global Warrant, registered in such name or names as may be designated by such Holder, no later than the Warrant Share Delivery
Date (as such term is defined in the Warrant Certificate). If the Company is then a participant in the DWAC system of the DTC and either
(A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
by Holder or (B)&nbsp;the Warrant is being exercised via cashless exercise, then the certificates for Warrant Shares shall be transmitted
by the Warrant Agent to the Holder by crediting the account of the Holder&rsquo;s broker with the DTC through its DWAC system. For the
avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Section&nbsp;2(d)(i)&nbsp;or 2(d)(iv)&nbsp;of
the Warrant Certificate, such obligation shall be solely that of the Company and not that of the Warrant Agent. Notwithstanding anything
else to the contrary in this Agreement, except in the case of a cashless exercise, if any Holder fails to duly deliver payment to the
Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of such Holder&rsquo;s
Warrant as set forth in Section&nbsp;7(a)&nbsp;hereof by the Warrant Share Delivery Date, the Warrant Agent will not obligated to deliver
such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant Share Delivery Date shall
be deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company maintained
with the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise the Company
via email at the end of each day on which notices of exercise are received or funds for the exercise of any Warrant are received of the
amount so deposited to its account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;8.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Destruction of Warrant Certificates</U>. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination
or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled
form, or, if surrendered to the Warrant Agent, shall be canceled by it, and no Warrant Certificate shall be issued in lieu thereof except
as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Warrant Agent for cancellation and
retirement, and the Warrant Agent shall so cancel and retire, any other Warrant Certificate purchased or acquired by the Company otherwise
than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at the written
request of the Company, destroy such canceled Warrant Certificates, and in such case shall deliver a certificate of destruction thereof
to the Company, subject to any applicable law, rule&nbsp;or regulation requiring the Warrant Agent to retain such canceled certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;9.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Representations; Reservation and Availability of Common Stock or Cash</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery hereof
by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance
with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due authentication thereof
by the Warrant Agent pursuant hereto and payment therefor by the Holders as provided in the Registration Statement, constitute valid and
legally binding obligations of the Company enforceable against the Company in accordance with their terms and entitled to the benefits
hereof; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws
relating to or affecting creditors&rsquo; rights generally or by general equitable principles (regardless of whether such enforceability
is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the date hereof, the authorized capital stock of the Company consists of (i)&nbsp;100,000,000 shares of Common Stock, of which approximately
<FONT STYLE="background-color: white">2,308294 shares of </FONT>Common Stock are issued and outstanding, 420 shares of Common Stock are
reserved for issuance upon exercise of outstanding stock options, 722,644 shares of Common Stock are reserved for issuance upon exercise
of certain pre-existing warrants, 29,514 shares of Common Stock are reserved for issuance upon the vesting of restricted stock units,
167,849 shares of Common Stock are reserved for issuance pursuant to potential future awards pursuant to the Company&rsquo;s equity plans,
and 11,015,426 shares of Common Stock are reserved for issuance upon exercise of the Warrants, and (ii)&nbsp;10,000,000 shares of preferred
stock, $0.001 par value per share, none of which are issued and outstanding. Except as disclosed in the Registration Statement, there
are no other outstanding obligations, warrants, stock options, restricted stock units or other rights to subscribe for or purchase from
the Company any class of capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued Common Stock or its
authorized and issued Common Stock held in its treasury, free from preemptive rights, the number of shares of Common Stock that will be
sufficient to permit the exercise in full of all outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent will create a special account for the issuance of Common Stock upon the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which
may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon
exercise of the Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may be payable in respect
of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for shares of
Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue
or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall
have been paid (any such tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender)
or until it has been established to the Company&rsquo;s reasonable satisfaction that no such tax or governmental charge is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;10.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Common
Stock Record Date</U>. Each Person in whose name any certificate for shares of Common Stock is issued (or to whose broker&rsquo;s account
is credited shares of Common Stock through the DWAC system) upon the exercise of Warrants shall for all purposes be deemed to have become
the holder of record for the Common Stock represented thereby on, and such certificate shall be dated, the date on which submission of
the Notice of Exercise was made, provided that the Warrant Certificate evidencing such Warrant is duly surrendered (but only if required
herein) and payment of the Exercise Price (and any applicable transfer taxes) is received on or prior to the Warrant Share Delivery Date;
<U>provided</U>, <U>however</U>, that if the date of submission of the Notice of Exercise is a date upon which the Common Stock transfer
books of the Company are closed, such Person shall be deemed to have become the record holder of such shares on, and such certificate
shall be dated, the next succeeding day on which the Common Stock transfer books of the Company are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;11.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
of Exercise Price, Number of Common Stock or Number of the Company Warrants</U>. The Exercise Price, the number of shares covered by each
Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section&nbsp;3 of the Warrant
Certificate. In the event that at any time, as a result of an adjustment made pursuant to Section&nbsp;3 of the Warrant Certificate, the
Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than Common
Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time
to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained in Section&nbsp;3
of the Warrant Certificate and the provisions of Sections 7, 11 and 12 of this Agreement with respect to the Common Stock shall apply
on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment made to the Exercise
Price pursuant to the Warrant Certificate shall evidence the right to purchase, at the adjusted Exercise Price, the number of shares of
Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certification
of Adjusted Exercise Price or Number of Shares of Common Stock</U>. Whenever the Exercise Price or the number of shares of Common Stock
issuable upon the exercise of each Warrant is adjusted as provided in Section&nbsp;11 or 13, the Company shall (a)&nbsp;promptly prepare
a certificate setting forth the Exercise Price of each Warrant as so adjusted, and a brief statement of the facts accounting for such
adjustment, (b)&nbsp;promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate
and (c)&nbsp;instruct the Warrant Agent to send a brief summary thereof to each Holder of a Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;13.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fractional
Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall not issue fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any fractional
Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such
fraction to the nearest whole Warrant (rounded up).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence
fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed,
the actual issuance or distribution in respect thereof shall be made in accordance with Section&nbsp;2(d)(v)&nbsp;of the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;14.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
of the Warrant Agent&rsquo;s Obligations</U>. The Warrant Agent accepts its obligations herein set forth upon the terms and conditions
hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the Holders from time to
time of the Warrant Certificates shall be subject:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compensation
and Indemnification</U>. The Company agrees promptly to pay the Warrant Agent the compensation detailed on the fee schedule mutually agreed
upon by the parties hereto and provided separately on the date hereof for all services rendered by the Warrant Agent and to reimburse
the Warrant Agent for reasonable out-of-pocket expenses (including reasonable counsel fees) incurred without gross negligence or willful
misconduct by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify
the Warrant Agent for, and to hold it harmless against, any loss, liability or expense incurred without gross negligence or willful misconduct
on the part of the Warrant Agent, arising out of or in connection with its acting as Warrant Agent hereunder, including the reasonable
costs and expenses of defending against any claim of such liability. The Warrant Agent shall be under no obligation to institute or defend
any action, suit, or legal proceeding in connection herewith or to take any other action likely to involve the Warrant Agent in expense,
unless first indemnified to the Warrant Agent&rsquo;s satisfaction. The indemnities provided by this paragraph shall survive the resignation
or discharge of the Warrant Agent or the termination of this Agreement. Anything in this Agreement to the contrary notwithstanding, in
no event shall the Warrant Agent be liable under or in connection with the Agreement for indirect, special, incidental, punitive or consequential
losses or damages of any kind whatsoever, including but not limited to lost profits, whether or not foreseeable, even if the Warrant Agent
has been advised of the possibility thereof and regardless of the form of action in which such damages are sought, and the Warrant Agent&rsquo;s
aggregate liability to the Company, or any of the Company&rsquo;s representatives or agents, under this Section&nbsp;14(a)&nbsp;or under
any other term or provision of this Agreement, whether in contract, tort, or otherwise, is expressly limited to, and shall not exceed
in any circumstances, one (1)&nbsp;year&rsquo;s fees received by the Warrant Agent as fees and charges under this Agreement, but not including
reimbursable expenses previously reimbursed to the Warrant Agent by the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Agent
for the Company</U>. In acting under this Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely
as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders of Warrant
Certificates or beneficial owners of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counsel</U>.
The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice of such
counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in
good faith and in accordance with the advice of such counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Documents</U>.
The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in reliance upon
any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed
by it to be genuine and to have been presented or signed by the proper parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Transactions</U>. The Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest in, Warrants,
with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable
law, it or they may engage or be interested in any financial or other transaction with the Company and may act on, or as depositary, trustee
or agent for, any committee or body of Holders of Warrants or other obligations of the Company as freely as if it were not the Warrant
Agent hereunder. Nothing in this Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to
which the Company is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Liability for Interest</U>. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies
at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Liability for Invalidity</U>. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or the Warrant
Certificates (except as to the Warrant Agent&rsquo;s countersignature thereon).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Responsibility for Representations</U>. The Warrant Agent shall not be responsible for any of the recitals or representations herein or
in the Warrant Certificate (except as to the Warrant Agent&rsquo;s countersignature thereon), all of which are made solely by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Implied Obligations</U>. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant Certificates
specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the
Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense
or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall
not be accountable or under any duty or responsibility for the use by the Company of any of the Warrant Certificates authenticated by
the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds
of the Warrant Certificate. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance
of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from
a Holder of a Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty
or responsibility to initiate or attempt to initiate any proceedings at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;15.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
or Consolidation or Change of Name of Warrant Agent</U>. Any corporation into which the Warrant Agent or any successor Warrant Agent may
be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the Warrant Agent
or any successor Warrant Agent shall be party, or any corporation succeeding to the corporate trust business of the Warrant Agent or any
successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any paper
or any further act on the part of any of the parties hereto, provided that such corporation would be eligible for appointment as a successor
Warrant Agent under the provisions of Section&nbsp;17. In case at the time such successor Warrant Agent shall succeed to the agency created
by this Agreement any of the Warrant Certificates shall have been countersigned but not delivered, any such successor Warrant Agent may
adopt the countersignature of the predecessor Warrant Agent and deliver such Warrant Certificates so countersigned; and in case at that
time any of the Warrant Certificates shall not have been countersigned, any successor Warrant Agent may countersign such Warrant Certificates
either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases such Warrant
Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case at any time the name
of the Warrant Agent shall be changed and at such time any of the Warrant Certificates shall have been countersigned but not delivered,
the Warrant Agent may adopt the countersignature under its prior name and deliver such Warrant Certificates so countersigned; and in case
at that time any of the Warrant Certificates shall not have been countersigned, the Warrant Agent may countersign such Warrant Certificates
either in its prior name or in its changed name; and in all such cases such Warrant Certificates shall have the full force provided in
the Warrant Certificates and in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;16.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Duties
of Warrant Agent</U>. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions,
by all of which the Company, by its acceptance hereof, shall be bound:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent may consult with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and the
opinion of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted
by it in good faith and in accordance with such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Whenever
in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be
proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in
respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by
the Chief Executive Officer or Chief Financial Officer of the Company; and such certificate shall be full authentication to the Warrant
Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the limitation set forth in Section&nbsp;14, the Warrant Agent shall be liable hereunder only for its own gross negligence or willful
misconduct, or for a breach by it of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the
Warrant Certificate (except its countersignature thereof) by the Company or be required to verify the same, but all such statements and
recitals are and shall be deemed to have been made by the Company only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof
(except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except its
countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement
or in any Warrant Certificate; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change in the
number of shares of Common Stock required under the provisions of Section&nbsp;11 or 13 or responsible for the manner, method or amount
of any such change or the ascertaining of the existence of facts that would require any such adjustment or change (except with respect
to the exercise of Warrants evidenced by the Warrant Certificates after actual notice of any adjustment of the Exercise Price); nor shall
it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common
Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued,
be duly authorized, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered
all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out
or performing by any party of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive
Officer or Chief Financial Officer of the Company, and to apply to such officers for advice or instructions in connection with its duties,
and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in good faith
in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without gross negligence or
willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or
other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract
with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing
herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or
by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct
of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable
care was exercised in the selection and continued employment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;17.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Change
of Warrant Agent</U>. The Warrant Agent may resign and be discharged from its duties under this Agreement upon 30 days&rsquo; notice in
writing sent to the Company and to each transfer agent of the Common Stock and to the Holders of the Warrant Certificates. The Company
may remove the Warrant Agent or any successor Warrant Agent upon 30 days&rsquo; notice in writing, sent to the Warrant Agent or successor
Warrant Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. If
the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the
Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified
in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder of a Warrant Certificate
(who shall, with such notice, submit this Warrant Certificate for inspection by the Company), then the Holder of any Warrant Certificate
may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent, provided that, for purposes of this Agreement,
the Company shall be deemed to be the Warrant Agent until a new warrant agent is appointed. Any successor Warrant Agent, whether appointed
by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States or of a state
thereof, in good standing, which is authorized under such laws to exercise corporate trust powers and is subject to supervision or examination
by federal or state authority and which has at the time of its appointment as Warrant Agent a combined capital and surplus of at least
$50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities
as if it had been originally named as Warrant Agent without further act or deed; but the predecessor Warrant Agent shall deliver and transfer
to the successor Warrant Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance,
act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof
in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof in writing to the
Holders of the Warrant Certificates. However, failure to give any notice provided for in this Section&nbsp;17, or any defect therein,
shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant
Agent, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;18.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of New Warrant Certificates</U>. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company
may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect
any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property
purchasable under the several Warrant Certificates made in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;19.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Notices or demands authorized by this Agreement to be given or made (i)&nbsp;by the Warrant Agent or by the Holder of any Warrant Certificate
to or on the Company, (ii)&nbsp;subject to the provisions of Section&nbsp;17, by the Company or by the Holder of any Warrant Certificate
to or on the Warrant Agent or (iii)&nbsp;by the Company or the Warrant Agent to the Holder of any Warrant Certificate shall be deemed
given (a)&nbsp;on the date delivered, if delivered personally, (b)&nbsp;on the first Business Day following the deposit thereof with Federal
Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, (c)&nbsp;on the fourth
Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt requested),
and (d)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or email attachment at or prior to 5:30
p.m.&nbsp;(New York City time) on a Business Day and (e)&nbsp;the next Business Day after the date of transmission, if such notice or
communication is delivered via facsimile or email attachment on a day that is not a Business Day or later than 5:30 p.m.&nbsp;(New York
City time) on any Business Day, in each case to the parties at the following addresses (or at such other address for a party as shall
be specified by like notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">MetaVia Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">545 Concord Avenue, Suite&nbsp;210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Cambridge, MA 02138</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Attention: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
to the Warrant Agent, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Equiniti Trust Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">28 Liberty Street, 53rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">New York, NY 10005</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attention: Corporate Actions - Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For any notice delivered by email to be deemed
given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the next Business Day following
such email, unless the recipient of such email has acknowledged via return email receipt of such email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
to the Holder of any Warrant Certificate to the address of such Holder as shown on the registry books of the Company. Any notice required
to be delivered by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding
any other provision of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice shall
be sufficiently given if given to the DTC (or its designee) pursuant to the procedures of the DTC or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;20.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Supplements
and Amendments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company and the Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global Warrants
in order to add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants or to surrender any
rights or power reserved to or conferred upon the Company in this Agreement, provided that such addition or surrender shall not adversely
affect the interests of the Holders of the Global Warrants or Warrant Certificates in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
addition to the foregoing, with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority
of the shares of Common Stock issuable under Warrants which are not beneficially owned by Affiliates of the Company, the Company and the
Warrant Agent may modify this Agreement for the purpose of adding any provisions to or changing in any manner or eliminating any of the
provisions of this Agreement or modifying in any manner the rights of the Holders of the Global Warrants; <U>provided</U>, <U>however</U>,
that no modification of the terms (including but not limited to the adjustments described in Section&nbsp;11) upon which the Warrants
are exercisable or the rights of holders of Warrants to receive liquidated damages or other payments in cash from the Company or reducing
the percentage required for consent to modification of this Agreement may be made without the consent of the Holder of each outstanding
Warrant Certificate affected thereby; <U>provided</U>, <U>further</U>, <U>however</U>, that no amendment hereunder shall affect any terms
of any Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the Warrant Agent&rsquo;s execution of any amendment,
the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed
amendment complies with the terms of this Section&nbsp;20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;21.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors</U>.
All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;22.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Benefits
of this Agreement</U>. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant
Certificates and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement. This Agreement shall be for the
sole and exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates. Notwithstanding anything to
the contrary contained herein, to the extent any provision of a Warrant Certificate conflicts with any provision of this Agreement, the
provisions of the Warrant Certificate shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;23.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement and each Warrant Certificate and Global Warrant issued hereunder shall be governed by, and construed in accordance
with, the laws of the State of New York, without giving effect to the conflicts of law principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;24.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument, and may be delivered by electronic delivery of a portable document format (PDF) file
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;25.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Captions</U>.
The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning or
construction of any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;26.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Information</U>.
The Company agrees to promptly provide to the Holders of the Warrants any information it provides to the holders of the shares of Common
Stock, except to the extent any such information is publicly available on the EDGAR system (or any successor thereof) of the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">METAVIA INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Hyung Heon Kim</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EQUINITI TRUST COMPANY, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Michael Legregin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Michael Legregin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;1-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Pre-Funded Warrant Certificate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;1-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Series&nbsp;C Warrant Certificate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;1-C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Series&nbsp;D Warrant Certificate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Warrant Certificate Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Equiniti Trust Company, LLC, as Warrant Agent
for MetaVia Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of [Pre-Funded Warrants]
[Series&nbsp;C Warrants] [Series&nbsp;D Warrants] (&ldquo;<U>Warrants</U>&rdquo;) in the form of Global Warrants issued by the Company
hereby elects to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Name
of Holder of Warrants in form of Global Warrants: _________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">2.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants):____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Number
of Warrants in name of Holder in form of Global Warrants: ________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Number
of Warrants for which Warrant Certificate shall be issued: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">5.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Warrant
Certificate shall be delivered to the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; width: 35%"></TD><TD STYLE="text-align: justify; width: 65%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 82%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 95%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Global Warrant Request Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL WARRANT REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Equiniti Trust Company, LLC, as Warrant Agent
for MetaVia Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of [Pre-Funded Warrants]
[Series&nbsp;C Warrants] [Series&nbsp;D Warrants] (&ldquo;<U>Warrants</U>&rdquo;) in the form of Warrant Certificates issued by the Company
hereby elects to receive a Global Warrant evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Name of Holder of Warrants in form of Warrant Certificates: ______________________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates): ________________________________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Number of Warrants in name of Holder in form of Warrant Certificates: _____________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>Number of Warrants for which Global Warrant shall be issued: ____________________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any: ___________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD>Global Warrant shall be delivered to the following address:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered
the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%">Name of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 82%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 80%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 95%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>tm263364d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="tm263364d1_ex99-1img001.jpg" ALT="" STYLE="height: 92px; width: 482px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MetaVia Announces the Pricing of $8.1 Million
Underwritten Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CAMBRIDGE, Mass., Jan.&nbsp;15, 2026 - MetaVia
Inc.&nbsp;</B>(Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic
diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and
Series&nbsp;C Warrants and Series&nbsp;D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts
and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwritten public offering is comprised
of an aggregate of 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series&nbsp;C Warrants and 3,920,316 Series&nbsp;D
Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series&nbsp;C Warrants and Series&nbsp;D
Warrants. The Series&nbsp;C Warrants are immediately exercisable, have an exercise price of&nbsp;$3.10, and expire on the five year anniversary
of the initial issuance date. The Series&nbsp;D Warrants are immediately exercisable, have an exercise price of&nbsp;$3.10, and expire
on the two year anniversary of the initial issuance date. The Series&nbsp;D Warrants are callable at the Company&rsquo;s option following
the release of a positive data readout for its Phase 1b Part&nbsp;III clinical trial for DA-1726 via a widely disseminated press release,
subject to satisfaction of certain conditions. The Series&nbsp;C Warrants and Series&nbsp;D Warrants issued in this offering are fixed
priced and do not contain any variable pricing features or alternative exercise provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladenburg Thalmann&nbsp;&amp; Co. Inc. is acting
as sole book-running manager in connection with the underwritten public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If fully exercised for cash, the Pre-Funded Warrants,
the Series&nbsp;C Common Warrants and the Series&nbsp;D Common Warrant could yield up to approximately an additional $24.0 million in
future gross proceeds. MetaVia intends to use the net proceeds from the underwritten public offering for working capital and general corporate
purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, MetaVia granted the underwriters
a 45-day option to purchase up to an additional 392,030 shares of common stock, 588,045 Series&nbsp;C Warrants and 588,045 Series&nbsp;D
Warrants, at the public offering price of $3.10&nbsp;per share, less underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This underwritten public offering is expected
to close on or about January&nbsp;16, 2026, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities issued as part of the underwritten
public offering were offered pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-292581), which was initially filed
with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on January&nbsp;5, 2026, as amended on January&nbsp;12, 2026, and
declared effective on January&nbsp;15, 2026 and an additional registration statement on Form&nbsp;S-1 filed pursuant to Rule&nbsp;462(b),
which was filed on January&nbsp;15, 2026 and became effective upon filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The underwritten
public offering is being made solely by means of a prospectus. A final prospectus relating to this underwritten public offering will be
filed by MetaVia with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from
Ladenburg Thalmann&nbsp;&amp; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About MetaVia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MetaVia Inc. is a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and
is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin
(OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring
gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting
in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726
demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel (DA-1241) is a novel G-protein-coupled
receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel (DA-1241)
demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis,
hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel (DA-1241) demonstrated
direct hepatic action in addition to its glucose lowering effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please visit www.metaviatx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release may be
considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &quot;believes&quot;,
 &quot;expects&quot;, &quot;anticipates&quot;, &quot;may&quot;, &quot;will&quot;, &quot;should&quot;, &quot;seeks&quot;, &quot;approximately&quot;,
 &quot;potential&quot;, &quot;intends&quot;, &quot;projects&quot;, &quot;plans&quot;, &quot;estimates&quot; or the negative of these words
or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended
to identify forward-looking statements, which include, among other statements, statements regarding the anticipated use of the net proceeds
from the underwritten public offering, the potential future gross proceeds from the underwritten public offering, and the expected closing
date of the underwritten public offering. Forward-looking statements are predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those
risks associated with MetaVia's ability to execute on its commercial strategy; MetaVia's expectations regarding the sufficiency of its
existing cash on hand to fund MetaVia's operations; the timeline for regulatory submissions; the ability to obtain regulatory approval
through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement
with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract
manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential
negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's
ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether
MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials;
impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating
to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on
the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the
Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form&nbsp;10-K and subsequent Quarterly Reports on
Form&nbsp;10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MetaVia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marshall H. Woodworth</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1-857-299-1033</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>marshall.woodworth@metaviatx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Rx Communications Group</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Michael Miller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1-917-633-6086</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>mmiller@rxir.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>8
<FILENAME>tm263364d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm263364d1_ex99-2img001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MetaVia Announces the Closing of $9.3 Million
Underwritten Public Offering,&nbsp;Including Full Exercise of Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CAMBRIDGE, Mass., Jan.&nbsp;16, 2026 - MetaVia
Inc.&nbsp;</B>(Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic
diseases, today announced the closing of its previously announced underwritten public offering of Class&nbsp;A Units and Class&nbsp;B
Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses
and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter&rsquo;s
over-allotment option to purchase additional shares and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwritten public offering comprised of
an aggregate of 3,005,574 shares of common stock (or common stock equivalents), 4,508,361 Series&nbsp;C Warrants and 4,508,361 Series&nbsp;D
Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series&nbsp;C Warrants and Series&nbsp;D
Warrants. The Series&nbsp;C Warrants are immediately exercisable, have an exercise price of&nbsp;$3.10, and expire on the five year anniversary
of the initial issuance date. The Series&nbsp;D Warrants are immediately exercisable, have an exercise price of&nbsp;$3.10, and expire
on the two year anniversary of the initial issuance date. The Series&nbsp;D Warrants are callable at the Company's option following the
release of a positive data readout for its Phase 1b Part&nbsp;III clinical trial for DA-1726 via a widely disseminated press release,
subject to satisfaction of certain conditions. The Series&nbsp;C Warrants and Series&nbsp;D Warrants issued in this offering are fixed
priced and do not contain any variable pricing features or alternative exercise provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If fully exercised for cash, the Pre-Funded Warrants,
the Series&nbsp;C Common Warrants and the Series&nbsp;D Common Warrants could yield up to approximately $28.0 million in future gross
proceeds. MetaVia intends to use the net proceeds from the underwritten public offering for working capital and general corporate purposes,
including to continue the clinical development of DA-1726 for the treatment of obesity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladenburg Thalmann&nbsp;&amp; Co. Inc. acted as
sole book-running manager in connection with the underwritten public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities issued as part of the underwritten
public offering were offered pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-292581), which was initially filed
with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on January&nbsp;5, 2026, as amended on January&nbsp;12, 2026, and
declared effective on January&nbsp;15, 2026 and an additional registration statement on Form&nbsp;S-1 filed pursuant to Rule&nbsp;462(b),
which was filed on January&nbsp;15, 2026 and became effective upon filing. Copies of the final prospectus can be obtained at the SEC's
website at www.sec.gov or from Ladenburg Thalmann&nbsp;&amp; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New
York 10019 or by email at prospectus@ladenburg.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About MetaVia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MetaVia Inc. is a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and
is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin
(OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring
gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting
in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726
demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel (DA-1241) is a novel G-protein-coupled
receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel (DA-1241)
demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis,
hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel (DA-1241) demonstrated
direct hepatic action in addition to its glucose lowering effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please visit www.metaviatx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release may be
considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &quot;believes&quot;,
&quot;expects&quot;, &quot;anticipates&quot;, &quot;may&quot;, &quot;will&quot;, &quot;should&quot;, &quot;seeks&quot;, &quot;approximately&quot;,
&quot;potential&quot;, &quot;intends&quot;, &quot;projects&quot;, &quot;plans&quot;, &quot;estimates&quot; or the negative of these words
or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended
to identify forward-looking statements, which include, among other statements, statements regarding the anticipated use of the net proceeds
from the underwritten public offering and the potential future gross proceeds from the underwritten public offering. Forward-looking statements
are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking
statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial
strategy; MetaVia's expectations regarding the sufficiency of its existing cash on hand to fund MetaVia's operations; the timeline for
regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product
candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial
and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in
the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates
and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely
basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials
that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known
and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable
laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising;
and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most
recent Annual Report on Form&nbsp;10-K and subsequent Quarterly Reports on Form&nbsp;10-Q. Forward-looking statements speak only as of
the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MetaVia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marshall H. Woodworth</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1-857-299-1033</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>marshall.woodworth@metaviatx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rx Communications Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Michael Miller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1-917-633-6086</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>mmiller@rxir.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mtva-20260115.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqK2bOdzZR+KYkxtmBybRmKrykrpfuWXytDAlI2cRsB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:MTVA="http://metaviatx.com/20260115" elementFormDefault="qualified" targetNamespace="http://metaviatx.com/20260115">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://metaviatx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20260115_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20260115_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mtva-20260115_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mtva-20260115_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mtva-20260115.xsd#Cover" roleURI="http://metaviatx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://metaviatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm263364d1_8kimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm263364d1_8kimg001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U 2P# 2(  A$! Q$!_\0
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M(+>/X.FQM_#UHWQ@@AB\1L2HU*49;R1X@D6RVR*$Q2<E?:^OY:>?;T/Z'/\
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M=27U=)&K*4Y ; & ORD D'D$'&.C9!.!@9-?G_\ \%$OV*_#_P"V?^SOXA\
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M;:MHWQ*^*?CUI[..")<?V!K6@31-:PR%YGM;T^8YWG'\KG[.FL:[_P $!O\
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M-ZWX?3Q_H%E8^.+'P=K]C<>)/"6EZ]8Z)KU_<:I:WA3\F?\ @ZOY_P""1OC
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M3W[/OB_PM!XO\/\ QO\ A3J'AHV8N[K6&\=^&[.'38Q$CR)J]MJ&HVMYHUU
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M* "LO6-)T[7--O='U6TAOM,U:SN]+U*QG7?;WNGZA:S6E[9SIQNAN;::6&0
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FN1X7&8C$8?*,.L+AJ,*.74<3.IB:>$IPC1CB:M7$<KKU:M6?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm263364d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm263364d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !< >(# 2(  A$! Q$!_\0
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MW_KD:</B0\1_"EZ,PO '^JOO]Y?Y&NQKCO '^JOO]Y?Y&NQK3$_Q6<N6?[K
M\^\8PO9^(DNE'$BJZGW4_P#ZJ[FRNH[VSBN(CE)%#"J7B#1EUFP,60LR'=$Q
M['T^AKC-+UF^\,W+VMS"QCSEH6X(/JIK11]M326Z.5S^I8F4IKW)]>S/1Z#6
M!%XTTET!:26,_P!UHSG]*S=4\;AU,.EQ.7;@2..GT'<UBJ%1NUCMGC\/&/-S
M)^A2\;WRW&IQ6R$$6ZG=C^\>WY8KK?#O_(O6/_7(5P&IZ3/I]G;3WA;[1<LS
M,K'D#CK[\UW_ (=_Y%ZQ_P"N0KHKI*E%1//P$ISQ=24U9M&E1117$>X%%%%
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0%W:QLH14N9+4****11__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm263364d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm263364d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !F B,# 2(  A$! Q$!_\0
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MGVG5-8\#VUA._P +?'%[=%5>XTZ]\/Z9J7@\W\Q>\GU3P3YVI7D]U?S37/\
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MPQ01WNL_#OXH_#R.VCBR-[&UT'QYKAC16 D2*>:99988I(@UM:-NR_S/]$.
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M9^,O%DWVAY9'&O>(_ASXHFTN.Z+-IVB6UAI-BEKIUC;VL7YK_P#!MO\ $$>
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MB;1M/UVTM)Y8);:6>VMM3M[F"">2WGEADFBC25XV",Y"(%_B[_X.Z_AM\._
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MPZ/'))(R-$ZG:T3C]Y&02-C!5(0*HWZ_+S_@F5^T*WQ@_9XTCPYJ>J2'Q?\
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M2N(?M&GPI'MDD\1^*4U&"VGD1YKA;SP]#/+)!:626_W'A!PG'BCC*CBL0H+
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MI?%]K:^/O!&EV<@:?6O!WB1O$?@_RXF 1O%UG:P7%C::5(8U57OM+U$7.WR
MMJ464_UNQ65O%%*L$)B227S)(F=Y$,A2/YA&[LB#:JC:@4 Y.,DDU-6TVVO+
M.:WN;>.ZMYH3;2VMPRM:SQ3[DFMVBD++\\>0^% =2!N.& \Z7CCGF/?U+.^&
MN&,9D=;W:^74,+'#5*5%M7IT,73H1J5/<U4JG*^:3N]$?4X_Z"'!&%P/]J\-
M<:<?\/\ &^$C&OA>)L-Q%F.*K?6J<(RC2GA:N*C3AA*TH4YUH4^:2E5K\L6V
MG+\,/A/_ ,%'S\9/@+\9? OCHCPA\9M+^$'Q U/PSK_AZX;3;?Q;!I/A*\U'
M4;OPXEO(D^D:]8RV4-S<:6+B1XK>6UU" P)>&V3R3_@E-\4?BGXP_:7UW1/&
M7Q(\>>,-.B^%6M7KZ=XF\9>(_$.G07&D>(_"^FZ=>6]MJ^I7D,,B:5J%RL@B
M54::[FD=6DC@:/GO^"EG[&^E? S4XOC/\*=-FT7P5KUU=6'B71-.0V]GX5U_
M71<VT%UHRQ.6L],\3I-_9>JVMN(K(+;(9(C).[-C_P#!'P+_ ,-5^)54EHV^
M#7BC))/+R^*O K7(!!X"W3SQK@X"J-N  !]R^'N#L1X8<;<5\/8&E@:&;X2E
M1AE=24*U?+:\)<M:E"I:<G2;C[6,^=3?M.62<;)?SQ0XQ\8*'TE? OPJ\0N)
M,TIU>%N(L3AIYG@*F(6"XQR>C3=;"5\=.M]4E7Q-9UG1KQG0E!NBY1FY0=_Z
M:E^T$9)ZLV/W[)QN.WY=XQQCC HIDEJSR.R[MI8XQO QG'&#CM_DT5_+D,7A
MXPA'DJ>[&,=:4'\,5'?VFNVY_K;4S3,(U)QCEE!QC.2BW4J)N*DU%M*BTFTD
MVDVDWHWN]ZBBBI.XHW=M'.0[HKM&N$+=!N;)4C@,I98Y-C;D\V*&;:)88G3^
M;O\ X+@_L+MXJT4_M=?#'1\>(_!^D1V7QDTZQBQ)K'A*&40:=X\,6UOM-QX'
M=T@\431YG'@R:)W'_$FT^2#^DQUWM@G@KC'(Y!)ZC_ZU<WK^AZ/KFF7VDZOI
M]EJMEJ5C=:9?:9J$4=U::A8:E;36EYIUW;W.^WEL]4MC/9W,,R&&X5E69)-L
M:CV,ASK%9#G& QF'DU351.O"+:<X*46U>_+JHOXE:+2ELI'P7B/P+E'B)PCF
MW#F;X>-6E4A.OA*J@G6HXZ$&Z,E+E;C24^3G<9<SCS+D;4;_ .9YY@&0S,QW
M%E=C$0T<A,L13RPHV"*1$4L"YVDL6)R0R _=//X?_7K]$_\ @I9^Q/J'[&OQ
MWO[33+"[D^#7Q!>Y\6?#/6)&D\VUTQ6 UGP SS%S-XA\)-/%)&+MGN+S13IM
MU.TEQ/<-)^=3QB-@"C*ZY4DLKI(J,T<5Q$RXRMU L=RZGB.>::.,+$D:+_:>
M7YMA\]R[#9C@6Z\,1AX59TX.#J4'9PE&M&,Y1A).E)M*4K)J[O<_QNXQX6S+
M@[B+-^'\YC2P^.R_'5<-1IKVRCF%&$:,J>*R]U:-*5;#>RJTX>TG&DW4I5TH
MN,8RE[)\)?V??C?\>GUNT^#GPQ\9_$2?PY:_VEK\WA/1CJ TBU"LUI:S&XFL
M[2XU#6VCN(=,L8+@WA>UFD>/RWA)\MU/3]5T75-4T;6+"YTG5]+NYM/U/2KV
MRGL+[3;VU(2[TZ^LKWS+JTO;*8/;WD$DLNRZCFV2>645?VH_X);?\%)OA'^Q
M]\-?B1\*_BUX5\87=OXB\57_ ,0O#OB'P1I^EZWJ-S=MH/AG2=1T2\TN_P!7
MTQXKO3HO#5E?>%[M-XDO=5U:--SPD)^9G[4_QLM?VBOVB/BQ\:].T"/PMIWC
M[Q+_ &IIFA*]D9K'38M,T[3[-M0@L;J\M[/6;^"S34]=MO.+KK-[?RD 2J3\
MS@<VSVOGN.P&.RFE3R6A7=/!XZNI*-:C^[?/S1C*Z;G56BNG"SO=6^@XFX3X
M)P/AID&?91Q4\?QAF$J.*S;)HU+T<LJ.KB(5,).SYH3A"A0DX\KBW6>JUOX?
MH>I7&DZE;:C"2IMI;?<RG:3&;J)70X!#!ED9>02-V000"/Z#OV*?#C6?@?6/
M&$D0AN_%^LB.QB92=ECH:.+"ZW/N^0MJ6HP,G^KF=$DF666WMVB_G=6*6698
M+:*6>>8QI#;0@O)>2AS)%;(O)W23QPQ@H Q,H&2,"OZNO@WX&O?"?P^\#^ K
M2(W6HZ=X9T2SN&MH]]S/J5Q90W^HW$FX,L4;ZC=W6[8$",KPHJQ1I&GT7$.:
M0R_*:V!I58?5J]55*#I-^Q5*RT7-R27O>TTY;7N>5P!PI2SWCO"9\\)3E+!X
M94.2G%RG&LZ=)7A[G+[-23:;FI>]+W>_H+$;I74.%<^9''&N]Q(YP\.,,Q!D
M#2@D9 EVJ0BJJ_5GP+_9Z?QC<PZ[XPN(TTB,I+:Z'"0E[=D".02WS +-'8,&
MV*(I$8RQ2@L.#65X"^%]KHC_ -IZ\W]I:OY09;6,$VUL=HVK,H*H;A6R75E(
M*&,\DU[+:7%W9MY]A<36EU$@.Z*:2&-54MB!_+90T8Y/DL#&-Q.W+-G\'XDS
M:KCH5,+@YNGR/DC4E91:Y8ZIQ<GNWK;IL?WOP/P;E]'%X+,N(:<JCHJ-2E1P
MZYY)*<W&-6-7V,4[)72E);:L^T=&T73-&M+?3]-LXK.UM46.*WA0+!&$C"_N
M> 7! &9G,DKG(:0[55.@ *C/7..GI]??I^5?-'AKXMW]K&EOXBMTFME48OK'
M;).G 7:T.T1;!MW9*9)=LG@8]ST3Q)I6N0+)I^I17:L,F-#$MTC *S++'QMV
M@@G"*.3@]J_&<9EN,I8BK5Q+J5;5&XR3G.F]$[J4DG]Z6SU5E?\ J[+,TRNK
M3IT\$H4*;C%*DU3A.*2Y4I1@VKZ7LFTKZ'3*0<D#O_A_G]:=4"2KALE1AC@*
MV2!@$!\GA^>0,C&"#S4JL&&1T'TKD<XIM7U6\;KF7DU_70]U;)Q7N]'I9KRL
M^]QU%%%-.Z3LU?H]QA1113 AE).0"05"D#L6=L1'/^S(H)'3!P<@D5_D8_\
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M;N*VM5M;.&WM( BK4C)*,4URVW26U_-]SZ"K^,3_ (/%?^25?L-_]E!^-O\
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M#@95U9<@'&>:_AL_X/"OA'X7T_5OV*/C5IUK'#XNU;2OC!\+=:E>29#?^'-
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M2T[[(XG67Q/J#07_ (FO+6-$'VNZLM2L;?PU'+-YS)%87,=N8TU#4!=?N?\
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M1XO21K>^EOKI[Z/4H$F>^:);*/[.;FZ_1G:I() +?+D^NW)7/J%+%E!R QW
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M:&*KTL3B:E6I4P+Q<$XU'"HG4:IU9TN3$02FYQJ1BL"X#G.=\A?']W*IA?P
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MK5;C1]6F:2:626]\/RNEE UW+*6O);![19Y-]Q+"]U+//-^T\+<;<.X_(_\
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ER0]I&#'Y$ZYZL.O/0<4445LHQLM%LOR]3TUAZ%OX%)_]PXG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 15, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 15,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">METAVIA INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">545 Concord Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MTVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm263364d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mtva-20260115.xsd</File>
    <File>mtva-20260115_lab.xml</File>
    <File>mtva-20260115_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm263364d1_8k.htm">tm263364d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tm263364d1_8kimg001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm263364d1_8k.htm": {
   "nsprefix": "MTVA",
   "nsuri": "http://metaviatx.com/20260115",
   "dts": {
    "schema": {
     "local": [
      "mtva-20260115.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mtva-20260115_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mtva-20260115_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm263364d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://metaviatx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm263364d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm263364d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://metaviatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001104659-26-004532-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-004532-xbrl.zip
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MM_QSW1)FZ_@1H.5@"D'C@T>H0VXLUD>74B6:0;JN0SI@]4//-^LT,US:TQF
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MU^I0KH\Q5')ANCP6*&4$F*1@1*F%,]/D@:X@,.BL=D?[JW ]DD9W$'"29O9
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M(Q#\=+,(DR^^WZ]EK^6998Z&* UN>,L7 _+3[3Q_!>P>=]'YX2N>6NT,-38
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M^Y=:)=.?KW8:Z]W4O26HS_/)DZ1"F;49(36+T JE;*%/@*B"'5B)<VW!H5E
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M7D6JZ<&X2,$#,A17FY6B"<-+#TE]_L_GI)LK.Z$<RX&I44PR@VL8,#9%L?9
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MR1RF*)K";C]/-SP2]Q4?C#K-<_R<]MNWM)_FJXI>L+6OQJ-UN0)A#><1)-/
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M+J<?#_Y8CD<N6C!0993CA:NE\7/%WZI2A5\SO+B-1L8#B]CKT'GQ2&Z).Y+
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M$^=%9>1+'Q+%(UXZCOM]6Y';"M_3@O3W&S>]UEQC72OT!X(G#>OY@3C)-D9
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M,8O;Q"J:C.O0JK1?P;E\H(.VB__N_<MN?%9/BW0VR!XC]0^.0,9[I^2Y.M"
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M.#TG_9164PK0D7V3:=V=F8S^2.[=%;^[.*_K79W7ERZO^G0\.CJ<'#SVIW.
M\&%/$5#S5=6$_2?[VC0&!GAOM:2+(>YK"\R:&_:YCHY4EZD]QZ/DND:7TKE1
M]N? :^A;@'72'!BL%49&I.L+-^\;CU3$V!ZZ&45MX&J?KXYOTN!YBQ;G[L,
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M.E%%&B%1J)>^(1]#*XE@ZKP&N!UPHZX:%Y0BHT!#Q*M"_WQ=X(2FLSYR\0Z
M-Y9N##UD:?U4951(U@@BK<?J]*W[0M(DT]6H+QIF!_WU^W\/O_M_]];_FTQN
M;E8:^K;D$X>P5F&MP+QT[96LC[,E*^[GM5)N4^1VZ5\ZU>>4&W>FXT52"^^_
MA-I(VCBQ16 .T$_L#&G9#WJ@Y*G%'?J>/PIR#"G"5P]WP\)LV2)U7#S::\9\
M/$<ZF0ND$FN23_#NH.$PKU09PNU9.LV%NZ6=I, 6RCD%SSR>ULIIB=L%*J'5
M5DWJ=:RMB9-%5C".F7H6&,,V;!Y&W6K$=",#"_S,<W5^D\J7_M-02"?#+%V
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M=4,R1S0430=A52!WP>IML1K[EGS^B&(=+(N8.#JORKIN_26N.KPNQ;YB:HL
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M6[D25!C_%12&ZX?A"<%(-PD5S7]08#D5^A/Y6P \L2_AYMVO7M>B5'U"X+U
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MK><]\CVL<"BSE%F^?_RA/^0;4IC7I;9BBE;+4LO]/;/!9>H391(?N&=;"DW
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MA$R/2SQ3JED3)8(C_ )GIK3B=V'75U$'+*_,.B ?"W[GS14?3-';;N8C0QN
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MA#'22."^<[R<08= 048Z4>SV,WH0M*EL8/BV#62%C9L1WDA4TZWF>M!U-KC
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MY5#0MZ9VS(@;0UOFJWW'S2*<#R"W])H@P:MGD.!!@ 0/1^ECWA$$\=Q39\Y
M@",%?_TR6EE_LW:-DZCIAAPCXH<J5DCVR<^$ $(>$YY#:%7!6824='L2,3Y)
MA.:&?G8+N5?/N^R&IQ RA"P>BV[2=*SJ6_EP%01_\A'%^Z/?W#O0.3R  3SR
MU. 7 A&[JW3FA^ N%<CX+$V 76WIQ3Z@A!PDZ:L2$_"$IKS-=#0B#O0@/<:S
M,:4KVW!*E.+K;":4(#I&K6TX-$6*#QL)7R;P0;@X,9<: $^'E@L". 0#H7!
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M97RT;./AUW++Q"FK5<YKND[E+#,(J3#DHLY?,'3TM#VB_8R+YYP/X?GW\!'
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M&U5RT!3)=# %,51@&!6IY=)%*]=!1]97AJM!5VU6J]M=J^W*>,%>1?3"Y.
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MM/5EYX_W\(]/1Y]WW_\_4$L#!!0    ( *F ,%P[.BD#SDP  ,;% 0 4
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M@K6!LP9'>%T6644_K?0_P4"(!G/YC!7\D'6^7-#O7:9X9LLX2)=7,U 48DS
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M$@H,1G+[N+X(87W]WDW@^@*#?@7$7;]W4W-])<0=P\16AMR%;M:W0]SU>U>
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ML)%-58DWP(]UQL,D,N 5^7AC<Z#?L^8)NJI!-*=MCL0,-ZZEI$OT*.F0TQ6
MS<'%?@)I4UL+90'^EH#LL R+#UN:A[&MLU(Q>6;9'.]*""@YW=B!(*R;V#G&
MO>"49^D8PC#V54<+I[\WW.],Z.6?N3\JH===8]]Q8D8.]P[;D-8C=_Q;DXMU
M#3CU!:T[3NTS$YWC+-@?.66VGDV%!8Q84J"VQA2\!:421'@H/ 3WP5! L3B6
M1,11%1US=39'I]>PD,'E^%T*<BY<A[Q=C$D6#KW?6SKVS::CC4,,4GNBB,7@
MU@Q99H/CA\H+T-G9I;7H]SR'4=QAS9BIYZ14]:RDJ2H5SB29O>B "N1"#.#8
M.@TPY33,SJ76SNX\&J;E<#:IR(8G!(4&<HAY?@FZJ2H4:%&6GE*AGX-*:);3
M,X([>VPKJ](VRC(8U462TL8S&4;?_)B2%WC[P93)+1(H8/&UA,00UNW$[WV^
M3'2'J/ID8.5MU!%9'LPE1T<NG"QH(_"FTWFI&^OP0TC!?K&G6:>CYT4!$.B1
M4N)O(&2>:#9@_26*^']N[&^]VHPV_KGY7_CYQOZF5-S<( /AE3R>JSZ43?2=
MAH&^$[!R7\4A$K%MX>C6MT3Y==P,?,GPFIWMO<9^8$\+)CWT:)H^E!D^W^?!
MR[\[A-[?\K^.49@Y\&RQ9S;,C[*&T+FV$$PZ(7K$6F5S!]WDAH*6Q\%34?TM
MZ0AT!#9VM5$,1Z/-IV!4QH8'71.OPZ86)@ *HF,QDK 0!/@OBBN!KMYS'DIF
M_#=XJOL,SW(HIHJ.);A0U D7-EH$UWD!CS(9YR I8@DB?][9,6 WN-E'4QX9
MO7M[XE5(6AK)L4+C(W-9)[+DLB)T&JV+,^S8S^_T>Z_@%/W0B883@8%WS8?I
M%)X1@ H7(P038Z-S$F_LJ%#C%/#*,+G;U84MC#>;=09_!\>YPFHTEI91-%[P
M6D?%+PLK6'0/!A%S.G+#<&_HO$#S<INX'&8%&V8K"4PXQLW519<!=&G:I0U6
MWN?@>XZ]7RQ8AZ215UQP\3?1"VY2^"ISV[9+S%'AQJ36TYY;+6+Z^#YB>KL1
MT\?W$=-[&[7-]B3[M$,&%MBEK^Z278HJ.0!@-,(]:+N2SRTH&#)OGN-A\/UT
M\;UD@63]\ZY)5J>O3?X!TZI)]PPR;*@33%=DK*6H*XPXNQ>/A:?/W.X2&3'\
M^ (&%NSSRL2&!Y,FVF?[[E@>UXHD'8>K!&9;:5J;I&**M4R,E'4A: 3SY9W9
M_;8%].S&1V W;CRU+A;AUWR6F[@5&T81GSKY;) ,MK\)<B^6R1#^#A^DPS U
M@2@>M"Q-7,K'4]#@I1*HX"<0EI^:LZ2Z"T&B08K-I%,0GNODMMZ^\2YM_V[$
MH2\^O7RKD&H"%KT!PUSW*/#N50FI;@')[?:"8:0N37.P-S^A2@^#PR%@:8@E
MGFT[VZ*@;*B?TRT$[&2LK\ZZ! 06.@ DJ12X: CZ@"N?R:$&532SI1U![$/Z
M+(T4HYK,YX,D(^VE?TU:#-^HJV,3ILPY&X[WDZOP]@@ 1NQI@K#DZ !^4HQ2
M.'JJ.6BNB=?9Z?=]O[53ZE6CF"K1A)4PAH/XN"2-S??CR(E*Z8C;V+<!AY*#
M KDDIS!(WD'X-D60=FWFCT[MW$:GPB.^X,Q4E63A)0:#!6LBJX-QD%=F4#Y:
M(=#0T47:>@B9NI!+ 0!KR*A%DO.A;W/8,0(9S4F1>@5;9L4Y:Z6OTU=AG;HO
M.J'(Q ;*W&T&":4PHSSD-DYO/"_$0HMIL0&"5A3R% LI]E.0,MIVA+0)&!G2
MV)71Z);ZJQNEW_'@%9#L1'35"66/FDCVKQG/AJDI9N.BI8Z,EBO2:J[1H6^;
MM9PK9NW/:@$##W#(:B)%Q:0,#5L-K#YH"Y83!,/V>P,%<^)1$#-.$VRJCFU(
M^@G^,A58A\Z7N2B>!I8YCM)2?N/P-.C8XLA5]\U'QHS9'!&- \C5-)E/G!*Z
M3N"_FYT7L1T:,&=COU-#%]W%TL%&?Y]JBA81-%#4?F^Y(&Q'QP&_7I)F59AC
MA^626P5G69L-[()[VK(]LM^]G_DB'7LC8O&<)G/_V92WQ=6@N$"6_CE+N31V
ME$R2,ZF IK0/1IJG*D^R&GEC"0J5@.C]93?>V=EI48;.&_BJSK(9V/AX=T)D
M8<S<FY+-& :S0\@$5S8P5X +(.BPO^PU+]']2L]3$(5VO;A@GK&.!HP4FHWF
MC^G=%_Q:$AC-R[C9F0W/PX2+N,!W0S 8*W]>!6D2N#KPQ@:PGH2D6#JMUS T
M\(U?[Y^<XM8_*Y,)L@1D!19_!,6;#!.IPCI[XZ;C6FU'^Q4W;=,L, X[9N<&
M;"_SK?3UE;U^2M<CC F!C;HYG&@ DA!7!<1ZM4.[ /3")"%KS\N[A0JW(:<)
M-A,P-0UYJVJ-=$?,]FH@O\#&0XC&C0%8S+^!=+IZP1$8'W:UN_<,]JE/ -+O
MA40A2_/6RT!<L1Q) IJWPW&+#.V^DG2E3AL[ '^7!\E%&KI*S0JY4:P+5:E3
M]V F#Q3IXRO,3'<59/>WQC18HDET20);"6[7W>]^!./YTM1)8,BYXUUCMWNU
M9-V3^V3=[2;KGMPGZ]9EQUPO4/5=(U4=(2I\/Q/_;0E0'0>Y!*<<L5GSR;C%
MAN5,1?(<BB;B7=:A;J4@)3ML+6B8P'##%/I>&JL3.ABA ];N-8")8U\\4G@^
MY$-38R+$ 'Y( PMO=<4;?CS+;40N.#6Q-E>\V(!00)_P[M-U<W*',DI,E@J]
MW C'1@I)YWD<A/3Z'B+7W!+?9T_8S? 1_0%J5-;O?:1E=^0^]$E!!&QX-F#-
M0?F2..QR#W4!7,BA&AC,_5;P77YJ[C[M,G7+A4TMB_@]@3OIU_^@P5C#W=C(
M<X!BS""!K!&;82S)M4P] W?QOOSA!/?B.\LMSK_**RF'1TWS:C;?.B;RAM>P
M4$C$ "N![PFNA\C,"@F)H'.];00G.M&6 (>AD+%?\/V-=TQ'PMLOB>[>2LF@
MP)BAN^\2-[T>DK L<C2TO^)R*5 E"46KI!"F@\E#ZE D7.@<<6%@/W! ET9"
ML P.7, ,1&[4EA%(QW;I-F/A9=1@1,LDZ<?>W5H[#.</RN)S<!)N,'L (HLU
ML2$M:C+4M(PF#[&IV\H%Z26^:X)]O,9I.7$2%Z:R/^;,0]4HF'&\5\SQP':H
MQOK1Q*R(&1<_#= 1&V[43B0Y1W4PH,>>'4%FIQJ(:6-RB1.4X5WH1L0=%>W'
M$TWF"0.+$DEL;@08"%7+\Q(BP2+RN=!H-[XX0=M@4IEIPBP3%QXYT-\AYM@H
M9F.FGUI&\EE8Z:=M:LD5&LSF"E2%DYG$:C@UJJ*-N3,RJ?9WJT<F2)@A!: &
M=[\X/73.=I\-TETFE5=WUF[HI81+R(7VP>@-R]-3,ZI#B)L,#IJ5"TX:HG.,
M<%0*;;22!.2,):*4%)3'10%O"Z<&9PUQH!HVS#O/I/?$EN5FAKZ]&>L$)8;]
M*/'H*I!&%I$RFJ;A8_<\XG+:UIUV'G"0&*H^+_(")W3#+TKU+P[3-6)<J!%W
MI>\.U-MA=>UG"X:R/H; ;LZ3D;>+:C[;J)0X%?0[J2E;P^B M.?.DCCQH6UL
MW 6_2. FK":=(5LR%V^0,#**U;9O,JR8W.7 /IY^!;./Z..Y&9%$6BTUF=9J
MY,&].B:(&T;D3MR*5!P_>D6)I-/G+[L[.,98*C286MKJ))&O]KH;4YW<5&HA
M55'BZ5Y.>+A,,;I&38)TWAT#>Q1;,X$+:# +I%;P[)TW[9&(.&9XEN559 &H
M3I:TN..-NHHEUNZ@39U,-#B"9C0KJHHBSRZ3$[\%=0M<4%%.]H=RK2K</ZG/
MM$2LQ2XG"VR)++F4VD"<7&+O7=Q %<1^B& S'#3GPX>:48 Q&_GH(=WP#^(4
M(*0#[**Q)Z!A-;)YH;&U,&47ZCW?(;8M:$9[!+N*O+6&GMFGUKJAUFHQTY_O
M8Z:W&S/]^3YFNBX[YEI^]O=QL[N<[G=%O_>Z9/\".WR)KBNCDV&93MF!!CD;
MVTLJ<TF%ET0N@4S+=>8,%9.'U*9GKXK?:"A.*4$LCKJ^G[@^Y"6&?HT85PXX
MS"\.-^9"T]%IB^Q2;VVRN3(VL8W9BB>_H,H=E@+_6*;;,R^?&7L[&QU?J:\1
M]\%"O&S-O2[<@*,5H<7P&OHDR4&<I,J>IF:-#Y/K;8W;!;X>P)R>P0OU>Z?)
M%\&^' G[OX26')!D*VI=B':-03.D6P:&G<8%L=?F-BNKDR]N&_@AQ<V3#-/C
M-(P6F]#%;;:@2&)-C2F[R+R8:6NPJ)M!; M*0[!GN,\7 REE'_*W)?U9H=&D
M80+4L#2$.SY';EZ=^L8%B/&#\^(2>4KHWQBO2PQD15T85$L+E(:!QG:TB8RF
M]DED&N./_2C7)49"3)Z'4R1.68J9%@SUX1PZ(,Y]XE0D)6);+:_ 2/R*&(E]
MCF0_("3Q/!M9P'D5@Y0KOC"$H&.B_"1=YV&P!*!O9Q/XWQB9Q"2Z"8[!9 #V
MK$)[7LNM)ZY62O6-MV'_M"+/\,\@@$I=-HSE3"UA8 &V1E3V7R!WOQ3[=U!=
M4DD*W'8L.!!\)0O=AH&XV.UO2%[6,68Z0LHB!T^E@?VY,]F#U?R O]W[ ;?K
M!_SMW@]8EQUS36/GEJV=K*@H,0KZ]%51?*Z:Y3R4B,60*M,\H)%<82Q$P.K(
M$UEQ60A3(9/ABX=/GBL=HP5G 8_ERB >LFZVM-A/;YG@R0_:C%S=:CF='^!S
MW(\W)@C7(A*6PFX%]CMIS.N72%"(OI'<=P/><S]%X-ZO&W7@Y>EB+3XPZ\8F
MY$2A!)AE]-HO,U8T7^2,!HDLR?2ISS4&="%WBU<4LE$79XK,#9.V">*J^V!M
M91B==KH82SL<XAG$"ERF:B4K#JM-T1ULOZNF"FRO@;./DB(9>8(+R-ZOZS(=
M,!#W Y< NXG 3=BANLY;,\["?BXNR>G%U%EE,$>O+"?M^TO0!]5Y.G5DRVM7
M0;T4-@5_2^D, X,M@F[A)G(?LUFU-!\3CK35>$;5YLP/?M0R%0;GA(%KY:2#
M2(EV/'_%<OCVRAY.:TL+/9XW4T+''5U@A)I(]PL-:\5IX?MW%.T;T$$8[S:\
MD$C-F=M<?\>&1?#7DMFW(ANL 7S1M@1^K8\=7XD>#MANE9-:G-D14E8/ALP7
MU?Z0[:9SF+T*'SZUL2Q=8>[A3?.126B"T^#Q7CJ_CKCTW(R^=)*[>9(59\7,
M>#?.K[!:G?/1DL&YVF3W>TMG6^_((Z:(]91AJAG+PI1:[./8M4@$R!:$<-CQ
MPO(8'6%<:##"ATC*)O[Z(JZ!W4>F<:6L&PP9?/HS:A)O\"[E+%.5^-W4#E*3
MOE4NXQOM().Z2C6RQ:%":%##2FK?K>'%<\Z+E8:Y9/@);6_]FK*Y*=V/^6#F
M:KWVNUH,#+A2:'6A<D$"7=W\@(YS##W@I(3\MR 8X;3+M." P"9HGJ^=TMG!
M<JXT@H"[ $OG7D_74=Q*283&52NI29&3TMJ@N)C,(98J-S9SRV;P3U&<C>4G
MP";7)8]UH6^'WHN"\=E@&6\:7)%HE%;#4K7!)O024O^K2FNTI+-1$&%L!<@@
M]?3-XW^EF0T'?J6)-3S'7S^S70=*,#XJ7Z3*.X%X6/VZ@@EB)]JW;LDZS0L7
M  ,W1(3I>"X'#:&\R!8<PE0DP[D)OWK3O-WO.6A$SFF[JY"8Q <;=@B2F5%@
M%'>/ BW C=P1^N="5DRS[2OI1;8,OD(Q1G4 .EE%R:>Y&;#@'MSV/F[E8+NE
MXK1"X*AF9BHVKW(;3M&/;9-AES7!!$[-;G&;*7.%83KDXS/'? YS<8J6-%;X
M@4&?Q5PJ*057'.6.'= 4W)]8"/C^,Q"T(=ZZF,$R8CR6X,JN9"*CPD'KKP.(
M2?-W=1.WBN63E+ZCDWRQO=CO24&NG6)M%GS2N3T]AI;JB+8R9"GO#LNX];Y"
MW)84_GEGYHJ6;1UT?M:C/>;HA&WC=27Q:=E]&GO:<"EIX=OM.1QVEXT96TA,
MX/8VK#C?5B;CMM5?237$B:"QB=O$FO(Q5YF!2X>#EH,"#F;4L>3:5*U;SFMF
M\O'VTZ<_,>R77"/)OU+'*8-?<P'Y;JX+EU)7_<314[R5:0*YW"ES7]<%B"U8
M4"_1=A57KX&4=L%C N22S1LV(I\0K);JU\G%(424KMY9YF W>VUAU\B&?O9K
M2U>Y<8KCE6R;ALO2 OCSWSU1,",W,O^+/6QJ;^/M)-O%NZ4O68>U*A1'!=KT
M,UHQ[FH2[>?.6HF=MVPF=8"5##C+V&.;'?Z\^^+DTX>75?WB(?Y);-P.X%W#
M"A>U_SMM?SW3=LWQMPKJ>$.*#6,BB">=<%-9RI=*7-<"+W1E,?PJA85"_8T9
MLWK>1>?7,:<$,BU+6FQO;/W>AM_]0B+!FV&5N9XYRC53FY"*'!,S#FR+1*VE
MERV)N-+6>R'UT^]-D"V.+2<&P\RF,CW@ZBD,?"$2G?9HE98:SHGMA%29<3^Y
M,.AHG25>)?OOJL5[<B9%VH"BW#%#B.US;GED[DB1W6K9QE_NLXVWFVW\Y3[;
MN"X[YBO:Q#]:LS;Q!R#]"79-WC?XNNHN$#I>O67\;6;ZQ.8Z3*DH8,0AF)-I
MEK97"OL-X>&@S50C!N/8;T[[DRER;"6<(^;V.BH?>8FY"(]1I*+%Z)?U5_#8
M=/Y-W>>MC8?.CF^]ETZX7:H)"O,WIX;(<;5TC47JW)G<?GO;#3(J.'R=7!3I
M2)N;HV(VJ&,G?ZDS0.+2=OD"*L33M5NH!@F[Z38-J68#GL)J%><,[!O**2#<
ML&P8X+';EF)83 9@651N+1T6Y"5,IX#Y>@1\\2I6*":;5QA!-4'F@+8A4'.,
M"QD$34_%#8*'&78;)G($#OFYE7HZKF+C.-Z<#Y-IBM@S'FWH3U,HP L1<@3,
M ]I:Y*:'R4T,6)>FQ:*0X<VP!5WA</ZM%)?8X 0=>??H)<S*N9D;7:K8Y1?Q
M^0?S0FAF\KR\<"F'SKD#WM5'MM@;L\\T 5,W@B?W7#'-:=&F8!FS32_/TIST
M]#CCBW:2&X5[1^[,"4KPH-A4'[%?YL"W5V@N^L@T/-&C)9I&ZY\UYXCF1)@;
M1YK*J36?X0!HJM:>9AQ%=I2GIRD)C[MT5&Z+%GL!#:Q!!"5ZAJ.6K!L2K91+
MM>5OSC4^F%=S))[>.Q*WZT@\O7<DUF7'W,%VMR>S@72'U5PWT7O0;PC>KCK9
M/ZSV7T!;8Y4^9=OX2';L8->*.Y.H,QLQ%'W'JOJ*KNZ"?Y ^Y2&[14H5Y[@N
M32C;30_H4A .(]4$BL?&%HEM&DM'CIPG9*A0C@.5]B)3I/:B]Q_T8"Q]4 OU
M@\O.$Y1<)4,I-=#57OT>!_X<J)R.>@4/BX-C/OBZ6?TUM*7U\MA14/..5?84
M[&VW5!J)0;J+M5T(?:'J9L6:,6(V-  (QUR.M)RY\3O7!I+N<-A17!N ;0BB
M%0+&FRU&H4WO%)KO(-%R@53RX'#EQAPY$YBM#::7D:9T;U^=@HAQ,.!/WP<W
MCMN32TW17)19M-4Y3F;;'[&ME5HTVFAC6<&0&)8-\(I+V=Y2\Z[I<=E^(@^D
M^7@!T\$K@A^A[2P124Z3Z+K_9;@$&HWW>^-Z(@3!545<_V2Z<WIUD/ZHVT9L
MR9EI)C:(0<B,S4"R.)-&W0<Z<^N)?O'VM0D>M<E[B#]:%I)W,ZY>_F;3EJ<M
M?C'C=9!:P"4<J#G)OQ8SF6>'C1FU/HD^"H_)Y^O$$2U%JJJVQ3"2(R5=+!>,
M!_M:V;CO>/U-[8D/90&&!!ZHAV[\B4V)0^YL:J2A07_M!\+BL)$'2]T(XQLE
MZ:Z)=!QJQL8\)X^V&XH1'.(*M9IG.<BAYUQ C'8+]*S&T7"0)Z(8#_>:M_$3
M+TCG8%T9@-@&=O4#>&-AD:]T@"Y$BL76B,%OIWQ,VB$E9E+@)E-$AXS'<2,X
M!..Q#17 H,=U.!-F:,0R<O&F\[$S%"GB<[B]-GWB*U<$?!NH05[-YX7?,\4%
M;*#^MN T@7EV=8Q8IK3=<>FS"TL.1;M)$:QKHED3R;F?P+?@KMWFTO)849>U
MY-3 ?AMS*;J>M=3OK6PNC1>:2XVIOY(M%,0,EQM#T0JVD%U,@6$TQM@LF0:]
MOIH)U(8976H!>:*YBOW#&V<I,/.F[)]#3\VVF#\R[#8K2*..KF #A3NWPP+J
M]U8W@:(6"XADPP)FFX]>;O_P"]>F"<S5[*'H)LRAE42%&I>V\@2,9R4^<8$;
MT"A+Z];%Z+MU2'W+3FI>1-":M)X1 #IZ/<M'R82+YD\=JLEV-%(0IM!X7JJ9
MXJ:.+5ZV^_0U-AE7"]KN[MQ';6\W:KN[<Q^V79<]<P=;=SH*#SDYC,;3\(,K
M0@YB"SGPTKU,(Y/-&0:H_T5V.&+-T0-CX'PF95YV))7DR3B&.U&41N=:#U(.
M)G_G'G!T@-.SR*1UZW;CH"&93T$RCS"0G8)E6LZQIK9KX.Z8,/ 5@SX@-P+4
M/;+WX#&L.65BP\L2,_A\K@-\QL,T?6[1DB$66,S^X:S65#,(IPF3!5%(EIW/
MX)7M5";@W)4"8I<9=7TK'W/@+(_[CK'#[3FFD1-*DZ#;8UX I<M5^),-7;74
MK'/P%X#:V6CGQ"=E9+/<L<4;%KCTQB09*2BVKT?F#0D>EQJ^R'&KTTOL8843
MP<<SWK3H2X985VF-.F=,9Z#W:LU,]&3G)V.9N<GZ$!43_DBOWD5!U113,($,
M>_20?ZOA,P%RPB(U6G<8Y3R6;[&H<X<U''OXI"C/DCS]'R?[+-$)\UD3#D(#
MH90'#'&6584&5=A5:BY] U.25C9-3GR\NDB8=K:SY*,%RTQ#T>O,<)>%<[B:
MEO*G$-71;#+A0CH;;.$WUGL)MK'NEV6W_V!6(>BG\E+\2XN:@U6)&VO"P9HM
M"M98K<FA&$Y'V5C,IJX'=/<IBRT6O\'%FO/@$ET%W8*J_6H)@U6=,N_LDT[F
M[V^Z910520<EB<78/:NH<W"_!W(11WI).>(@-;HM7-^L=6&(.=6=>9MD@Q[D
MQK Z7(MF2B^6EC7LU.BLZ@(JCX8WWM:A@R LC*"CH?E\_VW4V)*+,O$DGZ:[
ML_E<@767I7*)[SI>W;3;::,H-[$I:AW<&IS"->FH6^A@MHPLG&\U^!6/R(#X
M6:>1?(>D9$79$+MT+/$/OD=YP<4SSJ\LLXC.C"=4P0(&B)+[!@GA_8SDK:;"
M2.<ZKVTUKS:M7%OLH\O))6B=6Z:PP@P1QUY+K]N@6KE56A8.9FEH<N'J2X?E
MKN5OULB:"()/2-H B2U"*8*S#V=,J>%G IMC3@E=$4+/,(L8>6L8>?U7+3%X
MU^5F>_K<DWA4\;'3*.[2P;;N#=E:=@VCEQA6R^O#."5!UCG.G&006^TR";F4
M*TG1K\ZO<34[*)\+#"CH11FE:%VB D0[ MXMMZ9OQP,)-KW(B,22GYSYC(;G
M!;V$8?%8:")R_->T8J07ZYS+]DCI0!YO<@7]7F,,G1-9ZV=7D3DB.H/[IE'R
MPC7W2*1T 1.WU9$](?5+%'^;+WSGR/1U\!P3#@!;)8CVEZ_53LQ3CN@IKC;C
M_0.B/E%N_;'C#[F]%P*GB/L/^)IIE68_;=!3'=[35BL-3-=7&[N.:$*PV$XR
MX.3$#965_[GM)%/8]ND.XQ&ID8L&*891B+/<[B6L+DSFF]B'=!6E:C"J"X_>
MKKYV3"3%ICM'IYUI3?3.L>W*PU4UO0\$Q:WG+J7B1C**/:?7) ;;9U0CA"W_
M:TI\8>[!P]VK$BYB1)(5<L[:3K4&7)TFLO$*&U+B/4U()_&FV'0K&[0>Z8+4
MV"P=\SF8HWHQ/'NU5-W"4X]/7IM<67@*Z%X@YF[<!43R<DP,XS^.+S \%$88
M.^88C&UDR (CF\#M%*B!?3G+ZX[3H&U61:F[CN32#4 ^A+XI)WDZAAB'M?A=
MXF+ +L%D,#V121*RO8$_AQU>.T>? INOF*3#?L]Y6U=G=1G;QNMT$TP=+R^=
MN<PVZ=)(*?=\:]UN6A=L6X8)W]XW=M2B8[&YK:P--1J92FF&*NICPO" ,%=!
MBV;?J IV9,9EP:.W6'MWE.65IBV6#O)$S4V\P>:H:*P36#2J+!UZC/:QZX*(
M,2E5,!(3>F5Z3'" :8$]L2Z(3!EV!O"GD6R6/PK82AG_L,+QHB;=C)LWBJYQ
M'X]0A9P<-.8<&X0GB-U._*7GI.MW$@G6M-I7&IBV2-D>L$8 '#K=5H#_P!;)
M,:_%X WASZQ"V)#9Y@O'*BO4/8LQ 3LHS(BDYB.=L=6/82S(W<\-[M[G!F\Y
M-[A[GQM<ESUS!WF(#RS](>,N^[U]<@[MQZXR]=VEH.V&Z9."!E1-4JT9L/1G
MNP]AY]7G4ON&EE8;5Q>%;HB->@&_V:,5XWL>,Y_4!5/UII/)8?1\(EX[@<CT
MJW&4"7LSK!HN6Z72M'T<:WP<7$NTQ[<JVLS72*X0&[1W@=O@RGVC;Y7%WA)'
MT#3[44.&%_Q^KG)U(19Z$%:$+6T*C_W.RFT&>-ON#]J<@$\PI?QH>W!#-R''
M[C/,W=2DX@LCG[8(VRECUA%]#KJ3!K%?:C5H:=#"?CAD*+H/3J)!B;T3J4VK
M[@B#-T%_3;/#FBB??=8:2_.*]N/>O?UXR_;CWKW]N"Y[YGHGP'<] EJ/UWU,
M0EC-"6K6.7 Q4>.RO784Z-@*%(/2:M;F</(!="3J=HQ?;4:ZXM4OMC%<KXL>
M2'UM$P0?YR7&M3G?B_D@6R&4,]BJ5"-LL=P!@XDM.VSM]@&3.,:L/B]*6!#Z
M'5542O2(\O@VA]4 QDC9$8Q %RAS\'. O2 ''* O;)=I'Q_?[S7"W4YQ<JG_
M74JEZ<:AVW&=TA-)9J)]+FU&$'AIMFWV8!3"H=Z&.FJ?2H83>;B_4H-;0@R1
M!^J3LBV#[2-::S0Q"$J.82P-Y/.Z_G6@\73<R19ZQ9KYJ!OLI)$S;1 G VO"
M%&T+F7<S%<DHIJ-.2?8%ZZ+(9GDM-(AI;O\)&P@F4XIHLA06B>>5@ Z7*7M
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MF<-=V#+%OW/_#0Y!\Y!V\&/HL#EU5Y:3D5F*M'%/EQ3ABP@\S9Q)'8V.J"M
M5>B7&6GCK\&EJ4/.W#$M'ZHL0]K+=T6-\F<33/D<FZZ<:8)["^V!Q2SG+?A^
MJ8C6JTAQENGYO,*8(IY?9KV]0?GM!Z)9GJ$SY=P<BY_T2S4PD^,9H@8-P+.=
M,P-I4%=YMK29J<]+Y36:,8:L[R0YCQ$1Q$"YNVUI0_H/P;Z<^'W8LT6_#%LN
MIH@B'=N6 &82?*RH[K$6Z^X&MLLBX1E1E@0^[[AO4OC3#/5K#7J>4%F +XN<
M!%SCHV_%&/ZC^QC^+<?P']W'\-=ES]Q!6D]X,4/D['+2^Z4^U#E:"$S.LF(
MIAEK9*ZKBPY/#TPHUE84C!25/5.EM7]+W3TF9;>:/&>B1A])R)A#&,;L(&M(
M&GJRW2!Q <U5C3)8)>FHW6+LM@QU((]LCKFV#-"\J;1)Y!@G]GAT5+D;R&*M
M#E87'R^KV8C;Z.;_(>UIAJ8!:4M/P<<;"=:LV]Z%QGCTFO)0 /C",: TR[2=
M:(?*J=4>C%8R!ZG@*"@94*UVH\3YFNO=5J[A1680D63-3X;.H&DL;XXA123
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MV*R9N(QAVGYYFY2?E;A.'<RC,L(,@Z&CA0Y88E,0\GH:CNR_Y<HK4RK)9>G
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M[1*Y6M2OE>&@YYSY8XN)MQII%044@23@*_,!VIW2R01H#+P83:JK,P%^"PI
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MJ'OXZOWAO^@ _/7T[9N7_Q]02P,$%     @ J8 P7/I<[8$_4   8= ! !0
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MQ'R>L_]-O?T>-Q_?SV!H'4[^RP"/=7(BVHDG3%]I61^QLGJ0<BO51!(O78$
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M^7=_O?/O;M:_^^N=?[<I)^:S$HW2&TTT\F$[Q[=X9:"U#B%J*ZL)&1 _[)6
MK(I]\C@![ZV0O0MC+WW@W[U?/Y? B[[%*G!AUHWYQ^$_@8UE].IT&8.9+W)&
M@U7ER,IISI7XN#)'WZ/+;S7E64J6A0G&!&CI 1A6.6+.3K<ZMD7>I56-Z#UZ
M@ZC8R&##/#ST];KO&HDMUIT=9!\EZ0/R!)>J>M T53:B:A!<DC9UNVYL;X-.
MTPQ8+?\(&K"\)(\6 V*U81*]L 4BWUZ"!JW/L[FSM[Q*V%2F>5OZB5&0PJ01
ME$%72(/'QVQ!71EE"4?::2>C,>#,#W[4,16&O<3MJ>WCR>SH>?Z:B<+=.0\<
MK):^5SQO)KF(B\7#"+6JY2<:UIK3PO?O26<V5((0Q68J-"'Q15G8"'[/@45*
MUQ6S;[=LL ;P1=<2^%D0=GP5.C.@N6LG8+BP(Z18'0R9+VK\(=M#YU1P*7U2
MU-9500AS#V^:CTV8$OP#R1:@2$/B_#KBI%PS^LH)V19)7IZ5"^/(.+\R-;TT
M+G.]R1X.KIQM/9''G["V<.0)PTPKTX2!LEBK]CH'N)UDC,0,.UY8'B,CC+<,
M)M@8B^^(:[XJ"WMOWW2;DW73!K38#-2P6*I%KFV!N(>;%O>IW<H^4B)- E*9
M\E6<)/%P7C5@[V8WHI[S@- P0IPT?+SU->5P4Q ?H[SXJIPD]%GO:IDM8$BC
MGX+"!=XTTU)OI,X19<!)\0*9(ZQBGH?3+M." P*;H*U?>W=G3\GA5'D!W+I3
MVFUZLHX@JE3 &%>L9";P34)KBR PF4-,XFP=YH[#X&M1G(VK-< V9VQ.-06R
M1^Y%P?@L+L:'!E<DFF3UN$J[R!"ZA-1:HU:)EO3V("#FK- 3)-.XK?[7FMEP
MX->:V.'@B\ULGT()QD>)7923),0-*U_7,$'L1/O6+5FG1>G26N"&R!N=+D71
M$'>+;,$Q3$4R7AJDU9OFG>' X1ARI-I=A<1$-=BP0^K+@C!0/#TI2 &2?D3H
M<XDHID/NM>0B6P9_0#!&34 E64?(9X49L+ 9W,X!;DY5MZ7BU"5G #,WN6S7
MN0T'WJ>V,ZB;3VXP4G-:W ZHG'N5C5E]%ABLX9IK(B6-%7YH.&4Q)Y%)-B@#
MVK%#A8+[4WXVWW\!&VV,MRX7L(P(O1()V=V9F&M^V/GK@#C2_EW39J-B8AG%
MYDB3K[87AP-)5;13K&;!!PW<Z1@Z<AZZ$C0E\35,<-5SA6RL*FOKS#4MVR9H
MUZJC?<EXGNT0<JWMTW'ZE%':<BEIX;OM.1QVGXT96Z)+X/:VK#C?5B;CMM-?
MR92X1(37Q.T\2Z&7Z\S I5-KD$$!APGJ6')=HM9-=#0S^7#GIY_^S&1><HTD
MN$K-+ PKS:79NV$M7$K-Y8FCG_!6IK_4U4Z9^[HN[6O%@GHQM>NX>BW^LTL)
M$WJ6'-ZP>_",R+*4V4LN#O&<-"?G*@>[W<8#&U*UY+.?^+[.C;."*A)38$U)
ML+0 _OSW3Q3,R%>9_]4>-O6:\$Z2;;W;T?*DQUJ5XB\EVO0+6C%N,1 =%,Y:
MB9UWU4QJ2((,.%O+Q/91>KSW[.3#N^=U\^P'_).JKCHT=B4+KNHL=-K]>J:C
MB^-OE=1^@@0;8B+($IUQOSH*C4HDQ+(JM.P!_"J#A4+YC<&Q9ME7Z*QG3HDZ
M6E6TV-[8AH,M<534'N38R;8(,8T4ISIS%%;&]\"Z)XJJT.Y!WQ1W^55+(JZT
M]5Y(_ P',ZRCQ983,UT6<YD></52!+Z07TYGM,XJ)6EB;X^TRKE530@Z6F>)
M5\G^N^[PGIQ)D0YCN.^X=H)M3FPK;-R2U+GU8DT_WL6:;C;6].-=K&E33LP?
M:%.[OV%M:@]A]R?8"^# D.?JVU#J[G:UK!6;ZR@CJO^$(9B3>9YUY__ZO69!
MT>9I"X-Q[#>GS/T<JP\ES*K@W@EI,?$"<Q&J42S2B>B7]5=0;3K_KJDDM+'Q
MT-GQK??*@=LE1Z T?W,R@QQ72S,G,N?.Y/;;VVZ14<'P=7)19A,U-R?E8M3$
M3OQ2(T#BTO;Y NVN\IT6JJ&Y;KO%X>O%B*>P7L<Y _N&8@K(+*Q:!GCLEA\?
ME[,16!:UFR&':78)%TE A@MRNW@5:]PFV]<803W#>@!=0Z BZ!<R")J>FGL/
MCG-L9$@E#QCR<_/O%%>Q.(XWY^-DGB'-C$<;^M,$!7@0(2-@'HO6DC0]PFUB
MF+@T+99B#&^65DE3.M70UL(EMCA 1]X]>@F+:FGF1A,0^_PBUG\P+T15)L_+
M@TL9.B]*0A:O/;+5WIA]I@%,701/[KEFF-,22\$R9IM>GJ75NNEQQA?MK;P6
MGAVY,P<HP8-B4WW"?IG#S5ZCT]^^*6ROHZ4"=M8_:\\1S8G4M".H17.@6ZB[
M0SFK.SO6,(KL"$]/4A+U]LI1N:7X[04TL%:5.I$SC%JR;$A4*%?I??]P?F^*
M^68[Z9TL1C59THW6XXC>PFHAZ[3NK5!@]_**TAIV"U/L@ 6,H]5=G70F&!J+
M9,(2,?.WIJO[@MFT.WC(;CY%S8C]I0'F7+!3.>SL%#?$YL4"YHEB%G* Y'20
MV"7$%K?@*L':>%CD.QV,+7'2D9[N5A )LD.2L7"D-3%E.& 8PR'^J \?/"P.
MA%;P=3M196S3?^6QDR O%S.!";KJEKNM, ?=Q4IBBB6#$.H7R5M*9\ Q5Q/=
M9RX:X4ITZ6F"S4I5G77Q(=: O[8[5)P%JTO-R4YT7V#)8# ?"R-<SX1F:Z'!
M*M+2O=VK4U+Q#H0OZ?O@QG$W5-[>FJOB)#:MP(G3^2.V21ZK1AMM797I(&JR
M%8IW2_-VY.5J&436!F1/M1\OU"!N.JY:0[8D@[Z:FWQ5E)5&X_W>&-(84'5%
M$2=NF)Y27LJ6/^JN$=LBG#036U3EQ(S-$$PX+D!5IGLCA8F^>/?:!(_:YC/$
M'UT%,+KQ(P^-WK9Y-:M?S-A0VCTY&:5+VO^ZS62>G:J;*/5IZ^/F,=%)A<%I
M*;*T[EH,LW,D%X7W!;-;_NC>N/W-67^Z R9O%IC\Z0Z8W)03<PN;L[ZK2C"]
MT00]<O$G-KZ/N(.=D9^MPL ^$!:'+0Y83D\0WZA(V\^D%TL;&_.</%)0*'C!
M[$W1#O!L;3$3G0NH3MT*RT1Y- SR1(3Q-(NJ</$3#Z1SN*Y,0.PBN_H WE3J
M:]<*T(5,L=B:_?CMG U+.Z3$3 K<9([LD.DT;H%#,!Y;:AX.(*[#F32$1RXC
MYVDZ'SM#D7P]IV+7ME_.RMT"OM?@ND[D6;.%Y7>3< D;:/%8<IK0//MJZ5]E
MYKCC4FL/LPO%'I!\5]>IL4Z%<S^A;V'GWUX'XVJLJ,^_<-)=OXR#$7V>?S$<
MK.U@3%<Z&*VIOY;W$&"&5[L/T1K>@UU,H6&TQMC.C@:YOI[3T,49O=)G\+;F
M.AX#'YPKB9E?RV,X\L1LA\,@P^[R&Y1U= VO(3RY/3[#<+"^TQ!U^ RT-RQA
MMOWHJST&?N'&M,>XG@<1?0T'8JVM0BT=.TL"3!<5/G&%X]Q*2^N7Q8AV].SZ
MCI/4OHBH-5FS( )T]/.BF"0SSH\_=0I(=K.1 F!/^;R4,\7M[CIP*??IM][)
MVMN]\[)NULO:V[USLS;ES-S"IH:.P,/R&T;B*?W@FI2#V%(.O' O5XS)ETP#
MU'^1'8Y<<_3 F#B?2YJ7'4DM<3*.>LQ2"J-SK@<)!Q._<Q4<*7!Z%IFT;MYN
MT.8]J#:RC##TDX%E6BTQI[9OX.Z8$"J.01Z0&P'B'@OUH!K6\C&Q*<$2,_E\
MJ9"X\3!-!U"T9*BV*T;_<%8;RAD$;<)U@2B(P<YG\,IV*A-P[BHAL<N,NKZ5
MSSEPEL=]Q]BIV#FED1-+DZC;4UZ 5--5^),MS5IJYSGX"T"]MM0Y\4LMLEGN
MV.(M"URZ!M(>*2D:IB/SA@2/RTP5R&FGTTNEP4HGYH4ZWC0O2\:85VF-.F=,
M9R#W&BU"]&CWS\8R<X/U(2LF_)&NWD5)V11S,(%,3>@Q_U;I,P%SPC(U.D\8
M10FO/F)1[PEK.?;P25F=)47V+R?Z+.B$^:Q-!Z&!4) 0AKC(ZU))%7:5VDO?
MXI1DM0V34Y5=31*FD^TL^63%,M-0=)V9[K)R#M>34OX4HCA:S&:<2&?!%GYC
M/4MPC+$OE@]_C!8UDGYJ+\1_95)SL"IQ:TT8K+E/8(V5F@S%< #78C';F@_H
MGE/>MIC\!A=KS8-+=!5&8FUW7RTP6-V[YYUSTEO/^XL>F922I(.4Q'+JZBKJ
MJ3H<P+Z((UU21APD1[>C@C=+71AB07EGWB'9H@>Y&%:/:]$.@L?2B(:=&N4A
MK"CET?+&N_IN$(6%&70T-+^*?U?!:XG>&CS)+[[MEV1V4H%*S+NL4K?&7<^K
MFR8Z787'#39%354[P2E<DYZ\A9ZRE9&E\ZU'O^(1&1(_RS3:WV']L;)J;;ML
M*O@'WZ.ZX.09YU>VLHAR21+*8 $#))7[!A2*@YSV6T.)D<YU7D-?7FU:N2[L
MH\_))6J=FZ:PQ@Q1.;V.+J!!MG+G;EDYF"NAR96K+[UG^Y:_G2-K$ 2_VFB+
M)+:*I0C./NB82NEG0IOCFA*:$4+/,(L8>6L8>9TI;;GOOLO-\?3+3**J8K73
M2NY2L*W_0':F7</H!</J>'T8IX24>\=9T![$)J1<6ES2E23I5R/2G,T.PN<"
M 05=E$F&UB4*0+0CX-T*:_KV/)!HTZN,2$SY*;B>T?B\I)<P53Q6FHB,_VJ?
M6'ZQWKGL1DI'\G@3*Q@.6F/HG<A&GUU'1D7T@ONFA>S*-:<2\GC6K$J&NW)1
M>9LP"Z9.Q880G:L+4X-RU=O[+@!Z5IH+=8Q8WK*CT)#MU-;)E&%%$7NBQ?5/
M8:2L?-"(PY<B8T^2FO=W,4FOYC!1K&_&1IMSNGO>B!+>2*:C\5<Y(07Y74>N
MN''8+ K8<_?MV.WJYBYB5<[<383-N.;)LEVUQ!8MEHB?+5Y,8"TA:B=CK#]<
M,V37-?UE4$S(+=035GZP!-^RW2LWG-E56_"IR72-(\&"&0<V<=L^)<&Q!:]?
ML^RY_\6)>E69N^$JZB2,4OJBE0  /WA1)MSX^H@L_[*J.VRKLJ" 51=!>#@P
MJW75SC>!PF8Y)\<"TS-IY7SE3]F>5E8XW.QM8SUU+*UQ25<LGVL_<A]>+J9#
MWCR6MH!'4XUAV4%] K4-0U@[68KDK%C"V"EVDC3!Z]NR+&9Z_%"VN)?&:VHT
M0DGM9?2^,!U7:@/>M"R('<HW+2AKN$2$,GU<2N[L.%1T75U^^C V=]]+3$07
MHU]_!=.-+X"[6E<-M95V 6L-+CR$WFAB_KKON4K'M<5LR%$PNE \,"_;HRWP
MV5(,/T>+8*DY$?IFZZFO[:[W\O6;&,\=QZ35X'DX,+:'WQ;--<SH1O?U1F_9
M=T%;B-HVEY,TMTVFC$"00;S]59^IQ8GQKB_RLD0[^\PO86'LG D3,;JTU=6J
MA6M^R?",R<NU9(S]94JN)-BVY^/]*39M(=\VK=$#0\E.B>!8J&KB:)\/.R<[
M\#1)FJDTP2*1TBR^$B(=/4J;RS1M:XRU]">23)SR.U>%ZTX=XYW[5-I"+P75
M5*>:,Q<E6IZYI*C9\>[MDLG@?J\KZ\CZ7WX][5G-+2<XS%WQN&'3_N-'7"^
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M&L)9S)K8B7?8[1UK,9ILID"GTKSGU"B2V]G6?K9C./FFN"[-=^R @?U/QL>
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MU12FRC%A)8S>+1^7I+'Y?NP(IAD=<3N'UG_BL"@\=VU8=(XHQ\;,W_K0)M,
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M;-ZP7_&,8+54)DPN#B&BM+)GG8/=[@F"W:U:^MFOHM_DQEE!],:4;5.X+"V
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M@Y;-W\OJ0_0"O4,$SNT:=C/8/ET$96;>.#[KC-]AY LB8Y9CD34Q/"<\ \W
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M9>V!NV/"R%<<4?DE_)&-D58?CV$E>X\-87K,K#!+C? 9#Y-K3;TZ,80(-]C
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MZ&+TGU_!=.,+H%3KJN%I1<6=-#/!X,)-Z(TFYJ_[GJOH0LLR3XZ".0O% _/
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M&FDNF17VG]@L#/[!P29E<J:5(= 3&W4,WZ:UGTZ3K+7,846\+8;WQ\2)$BV
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M!T-A7RJ)+'8#++!*KA:2,8K_(D*$F8=(T#ZB3@-'I."B7MX&=32F_ATASW)
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M<D*+$F:>O591%!?0V;]*EDX.F[IX8\I!'R97<<1&.D4Z7;]A:4#W4U(]S1B
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M&'CP)'K#7:(?1R^3NKF-#5XW-OCY G7?/W]S]'<Z '\^>_7RV?\'4$L#!!0
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MJQ_3))(IT@%LSABUPH_P\?CVKZZ(;8MI=)BE5$_Z&A\6K.:EF3'D4%)D7W4
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M:ZD;:& =%R3.A9712*L.&;5X06+G+(K8KI$RUVR<[T3@AV1Q5E<FV27YSPP
M\J 3X+!,Q_#_43YRB<IB_HHU;9-]P>%X''H@8]6I\G8A'R/2<1"C[:6GV!LQ
M%%RI>ZP\A,],[TBCT<835=0$"F]M[$0.TE#!X<3 ,-PH0C@[$L0Y" Q)A4B-
MRS)+3LG DL?H8ARDT'1R=QS/6V K_1KV$L&RP$53.7S1/TBZEA==%GU<G>H
MV(&\!B>(JAL0-F+HE>$.9#]JB"2DRMS*Q#;*MHT$>3K*7#A2JE\*HN,SB1<4
M>QUDY_Q*?AUQG-J3 K\?:S/*55'BX+E*"^_PLFH<PBR8)E;=ZXM>9^29;<Z9
M'7[5F5_*4,^!&A>HS?!+"#(99QH+1$;#F$(#:[UI$ZFC[W;/'5PN@BAX*4B
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MV(2Z:=G$-WRW#\Y3Q35LP7!13#!F5EDGW&'/,D-.YA^Q[^=E_<]%>0&.\JF
M)QG8B,?5,%195JRX_]_51Z96U3FFS:R3I]L,>.EFLMVX.)O(M1 'P+*?Q>#8
M8T3QDA=UCM\Y!RFAQ\#,N=U%5U<;^U%XKO=,@R&I\OHSO7LH3%\LWW3VL&V>
MS9TU9\2(;=8HHB@.5=Z<*9]OL9#,H<Z[TMSM9.0$":&VL+L19[]_ZO&$P\<_
M/RZK'$P&U+ 1!>+4F;/DI/1^*?;#Z(4:P#]QE4ZG&2X'>/)KAK^XN9S0\^S?
MX$]P-$'"_D.2M:Y=&_-NK&&5ESNOC9-6NH+7 O"VG+5K*2:L=+I!S91\@V("
M1R"BF;Q*&[J=P$DZ+_M2_^\37='Y/O-+K]Q66J@TS);C9R],/(N.4 W6R(B#
MB%Z?F2,3\T^.WWV0S]IWQ7#/E(6V9H3WM@6VI>?+I#Y?9E*7F=2_'Y\A1B7E
M0IT(LT[D+N'BS9;'$+:M<^O>0/;ZJ&"4!3>-\R9NY5L@B,=[+-4TA.D1:I3P
M:B<=U!I7$ ;JEQ.3\8A,+IHXTOT5)2!*A7JS&=+G'MT"J\I[PLC&0BL>%&_B
MC,!A6"YG"!SF=L:[:2H).>9W:A1QL)USNUE(6DDHB75X2<VRL@5-=#&T_4Z?
M2&3F&W171TT(S#*=<;6WX+LZ_&,G\YL2 6C6:+Z+UOQ#@I4UMSW9G"GX5IEA
M7G,N.N-4DAA \H2]/W9V=8&I!IZ!X49@8K+$5U?6=BRC;T64+O-TK)U@Y+!I
M=/K=11A&MITW#/Z5C3H^0EZ4WKLJ67OCT P[WG5/X1O]H$U< 1=AGH4ABL'
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M:RQ+OOJZHQL3UH3Z)8J>=\72N>A21V@":8WON\D>Z!N 8JT]QOO2FC*HBZN
M$83(>2MK*(".&&5\ \S2) ]$G=\A)('B^%=RDV+<GIEL',89<TCPPTP_8WIF
M@B290(Z]%*B\JA A#KT;AKK['XY]5$,?R4[%RJXI]H485HHE"<^8&D\X,T[2
M%Q*V=)Q[FJ>@>C$[YA:]<J3&CT_ $(93IIDGMGGG[-P# M7[FV:*,BHELPB5
MO&UN!YJ<^JL%WK#YLB$OEMF093;DCM2$6I!;;#BMR/:X^C9#%,[%&44SE XG
ML/LNV!=*8JL!>:N4\J7*9%,\UF1?I R >0]J-M565\3_UH_+"U,5(/:+KH!P
M]%25A'3?T5BVSZ=1NYU$6GH.JYWCUFHLC5"48!:>E1=(E)FZE1 N8&D&Z0.;
MJ9U3)Y?$97S VA:,0QA3U2W*<]>B:QU\/>]_IP4K,[<^"8I=)XH:,)"P.;.X
MP"S B<T":CI;$"6B<6NI)-%%A@VER4Q:H+@,B5*Z+)7H%>9QY3$FQC!BSM@T
M0>#8P-XDR\&-F>>KC/33&]WJN]*)'I6<"S<><A)RZ[0>//3<B<FZ=2L=CI[#
M3^"1&- ^%N654T' T/2! )R]9,?6YG?*=KA,S6YOQ"/B<K2EZLD^1BN%WB8O
MI!)*JN7FEOC<<$\*<H<?PYA-(P5B W)<D&*1:M!M[3N%4A;:N3[;/A1-V>KB
MURXW8M0GN[6VRP(S71HCU1M1I=-#FOZ'('#"S$$)NL[FM*D-QQED$?C;8U@S
M3@KP."(U!!<$FL:R:1,F;Q4P=J@Z[WS3 4+*%T?M(8$)C ?YV(<.%Q-7^ZY[
MX?LX$&Q-\QL[V4[_[EW'%UO44]%B6YL!/GQ%=.]ZVDSE#K^0"Y!_9FO!B7:2
MOG(6MJLV@\J,Z1LD3[PEK2W7DUE=8=K2$'U;,<<<<;--[3'J*G%CF:-'B* %
M_3WT6>B0*DVCXXM5 3H&/ZK#ZAY^K7-*2>>,RHDJ'J*FW?KNFG9G@,/! T.V
ME']:TN301#C"T(K]B[L96JE9(OWPB=&X"1& <5*)>6I#IN1(CR\W.((RX*(9
MS*0B/2F#])VWX$\"DRSH+'K@-MCD:G1+XLC5Y6B93D<&$VX'@AJQ&X,?OKA5
M<>/U<'0@FJ35F3[2J4:5(T='U\W_Z?IJ,=#E$IN95W$L6.]63MU7!YMJ(;#R
MDEJ_FO1M*^;M3LAMOS%K/QG.@AM*UC8<P4+(H_&NY>QG#8HFJ[!5.EP4Y]E(
M,1AW4J$I)[J_Q40:%ESCGXV8.MU7_?TS":Q9#*8^",LTQOTI3;:VZ$-;VVUT
M5G1 WFD4T#"VS85A%)K/"9= H#VM'?$ >[5Q'?%>C:;9,=). 2&+%@I$6P86
M,JZ$Z91NH)MA>Z.[1O<5U1%]VT: WJL&\RF6EFLFSZ.];^L&RT)^55Z&2#2-
M@.KP@+,HKIH1,I('>$%M?W]7P @*@T"'R4Y< OQ+Z3AJH@M5\9FBSATQ^[!L
M*;/H@[@#@=5FH7%/> J7'T:/>=;M TH 7K_U)-:QSY3OF*)BL.PGE!_VP7^U
MXOH\+@.*S3 8';-ZZ@$*QS"X0=BCQE;^R0E )]@X1?(:88JQLI\FAI;)C':8
MCRP^)<)\1W^B<1EK+S-8TY;&LW7,;7N34J9]>;]FD(A#%6OESG4Z)LY$#:]%
M,HG,\ON6';R1"WRJYPOO_[P,[R_#^XMPESSY[G?)VXIC>,@2-.."6-P3?6^@
ML$[JQ'9N8>:(H6Q"[7MS%<),FBKO(5@R&IWW^7G-<SSB9G.U4]+&V6[]Q(MR
M.AK82H$P)6&K+;P!2=A"6EAY^0']&5O^7*GAB!IV)008$S037Y)Z2-H<1O\$
M:P.8*%$/<HV^2 7 2W3A+4KCK-Q(-'3K2RW[S_UNF;7[C]YV]&4=(LSF!WVE
M-;RO%6D.X%XETTZ>45M&QD4GQR\"06[3"U@V@2XO\&'(N7^CW7:/UMVR0&X*
MZG@>8U8P68T/%HC7[MHJ1GD?X7\U-_UR .KLRSI, \;_L9#SOC,.C>5E\G!=
M-63+_C&<P(@G+_K+H5W.KPL_;>MC @2T3KN77?69"$'8)3?8F04/(T\O'X1$
MWJ4=P)D\[IM@2DH/F*I>N_16_H)=-ZZC( 4B'MR9LGT9<N(1;+)\Y#1+^_[]
M&$S>SE!\FEQ59\M1"L0*[[Q/KF++*YWL<SEM'I?#QQ/0]0KI4(5K?LV>*.?#
MZ)C7"A$FE,DJ^I@\8_<:\9.G55EC5/04)$>)ND?8RG *-M(XK_'DHKO\5>2F
M9N;V1'8V2;&[/<+H@P!I2MW(8'C9L3"I7D%,0W%*OQI388>4QW E*;=+&.6F
M\JW2"W>M-4GLDE!D58M*E+<&WESEU+Q)D*I2,QPL&1,E4/ DJX,)FH4+]:7;
M;:!?UH(_,K) %9]#)<D0J1,2Q',^-G$2LQ[=!;"@_GCG$,#M-5C,32D3(4SP
M;=RH*),V%/44"YKACU3?%%3-.*N DZ25D)0J]RJX-*09]"&,8?/9%T1/7!YE
M!<"6$69O[INCI2CO*,BVK9(=9 <OBNZDD;MLO23&>>WTXS%]E,[S<YT>98(P
M7:N.J'E&@L2$10<:&X>+/U*8O2/,1VV.HQ8+4N&3)J5$P Z[R-DJ'F][&%31
MQ7',0EBX.HZY?3,5,!1,:9)JM&SJ-+](D\E4FHD@M SL ,X=$ $Z'DW&6@VR
M<7;*THO[_SG'..!9UM0EP\7L$<"L/]KLNOBLX982N$%8RF:[13$O+W';UXK*
MYE): )UP]R:/$"7! S'CBB8YP>XF=2ZJ0UN]7*SNUI&Q(2-MYOO:6M90":)E
MX0E2>A*A(5V5\9;,R3)&6>45*35W*OO;N"5;$GS."ZUY#QS2Z<!0->%E0DL-
M5,5'6Y)_BGMN6<;TEJ1Z_;I8)%$V&K 04X_W"7M?.W0%=D/=]F2XA5B'B+=T
MS@S0_;SJ3\<HW-QBN%#)VI:,^1*<:#-]O/@\>J#('2R?<D&6,3[NU,B=D42L
MQN*;FQN*:04,\SG/RRE.R5SM'=0206;-MC!>7'-SOD#RUN8RDKR,)/_]XDN(
MHN'KQ,E5X=EFU^:@T.9>E/-?F#UB-VZ<"B1B!QF#4A.<9\)U$^->')2*F]A3
MU7S82KMFRD[I@'J63^AR0[N8^70JV 5=;6?Z[05^MXV0>?@9>K1#1E]>%/ZG
M%[E4YIZ4WI''31X@"=_J2MO.1S ]FF2(4J(=U"YCN[5>ZN#O=?,WXV#ZLFX-
M&^&](9.JKVSHV[Q&^QE4Z<;AHO%DI)J X$([X8WJAX%(,1AU*!T<"'(_L$VN
MM-NQ'$BYXU6127Q:E@.D^239'70P* 2CU[-^( )ZA\5W(*![)5AR2H,$8R)J
M1$2V7RHW34/&*;FGUD 6?31;0MIR09^'I^@Z;+9YHP@\YE1,A<>1W%UR:XCD
MP_V@Z1&9NN )7;H\R292BB)KX+:V[,%8P%=A)N)<\U_#@DRQ/[ .>]BB"H/L
M1@@&[+HU=[$'CZIT4.N!".T=EH*YC$O4;5UR1AVQ<Z'K(BX*[+V%';U8<,I*
M C>@\,I+A<O"M4T&9$V78H(!<TMTEC#3BVG=DEH@FD-/6F/]@ZZ-EXHTUM&7
MDB(BV<F'5*JFJ$8_AHMQ8E!$KB-.#+'H-@&_G,'0@UN/E&'.*ZDO7'&*!B9=
M^V8"PJJ"R:V\@+-'IH#IM&-7U^IBUWK!QV9XP M>H5JSD&98L4WFB>(BJ,P-
M&5Y2[ST<. ^G')#5TK98')Z!&;0\Z$&" 3>B?W6OJ.YE:WT\Q/5WQ',B"'ST
M*G6@.XB$8FK#1A%EWF)ALKC@Z4%>"\Q]M%,K5$Q +:\?B'H8WJEZ.(1%?N_=
M1P<B[JPC/G%TTB9I.0G1DO'N[@IT>%NW7M@H:UP6.=+J.[CTD"O91>3.21#)
M'0P[?9('(D&G"R=!Q!D&/W;E:+LD(];@.3=/B^]O5]5#G:Q92K"9L72G'WW&
MFH<BI\5#@;"<W;E\',&6(LV5(R0! >1L2<'KB4E6^#$C(4:W6@!T!9:"2!3
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MON ,6/<C83ETHUV-;?9,CK85%?#[QQUKJC*ERF<T&N"ZX7I6NOQ2Q.>JP:7
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M=*.[T?UU-WSTR_WUU7&W<_3+^<D8GXS^'=U?WE^='Q^]MI]X^]J]/CI]/_[
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MN/L2K^DO%>V?+M)?./X_4$L#!!0    ( *F ,%Q'%.= ,P\  &DS   5
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M=F$M,C R-C Q,34N>'-D4$L! A0#%     @ J8 P7"#[UB3]"@  ?X8  !4
M             ( !60,  &UT=F$M,C R-C Q,35?;&%B+GAM;%!+ 0(4 Q0
M   ( *F ,%QB/$/X6P<  -97   5              "  8D.  !M='9A+3(P
M,C8P,3$U7W!R92YX;6Q02P$"% ,4    " "I@#!<L+&N#B A  !;N   $0
M            @ $7%@  =&TR-C,S-C1D,5\X:RYH=&U02P$"% ,4    " "I
M@#!<H<&1NYL]  #G/@  %P              @ %F-P  =&TR-C,S-C1D,5\X
M:VEM9S P,2YJ<&=02P$"% ,4    " "I@#!<N7/3YDRH   "PP, %
M        @ $V=0  =&TR-C,S-C1D,5]E>#$M,2YH=&U02P$"% ,4    " "I
M@#!<.SHI \Y,  #&Q0$ %               @ &T'0$ =&TR-C,S-C1D,5]E
M>#0M,2YH=&U02P$"% ,4    " "I@#!<^ESM@3]0  !AT $ %
M    @ &T:@$ =&TR-C,S-C1D,5]E>#0M,BYH=&U02P$"% ,4    " "I@#!<
M>967^Q=6  !SZ@$ %               @ $ENP$ =&TR-C,S-C1D,5]E>#0M
M,RYH=&U02P$"% ,4    " "I@#!<[\4>GLM'  #1S $ %
M@ %N$0( =&TR-C,S-C1D,5]E>#0M-"YH=&U02P$"% ,4    " "I@#!<SE2U
M/2,0  #H.   %0              @ %K60( =&TR-C,S-C1D,5]E>#DY+3$N
M:'1M4$L! A0#%     @ J8 P7$<4YT S#P  :3,  !4              ( !
MP6D" '1M,C8S,S8T9#%?97@Y.2TR+FAT;5!+!08     #  , !D#   G>0(
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>tm263364d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mtva-20260115.xsd" xlink:type="simple"/>
    <context id="AsOf2026-01-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2026-01-15</startDate>
            <endDate>2026-01-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-01-15" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-01-15" id="Fact000004">0001638287</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-01-15" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-01-15" id="Fact000010">2026-01-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-01-15" id="Fact000011">METAVIA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-01-15" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-01-15" id="Fact000013">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-01-15" id="Fact000014">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-01-15" id="Fact000015">545 Concord Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-01-15" id="Fact000016">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-01-15" id="Fact000017">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-01-15" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-01-15" id="Fact000019">02138</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-01-15" id="Fact000020">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-01-15" id="Fact000021">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-01-15" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-01-15" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-01-15" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-01-15" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-01-15" id="Fact000026">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-01-15" id="Fact000027">MTVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-01-15" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-01-15" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
